uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q17.1621 | Q17 | What gene does the drug Agatolimod Sodium target? | The drug Agatolimod Sodium is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene TLR9. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%agatolimod sodium%" OR LOWER(tradeNames_string) LIKE "%agatolimod sodium%" OR LOWER(drugSynonyms_string) LIKE "%agatolimod sodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2557', 'drugName': 'Agatolimod Sodium', 'tradeNames_string': '', 'drugSynonyms_string': 'Agatolimod sodium, Agatolimod tricosasodium salt, CPG 7909, CPG-7909, PF-03512676, PF-3512676, Vaximmune', 'linkedDiseasesDrug_string': 'Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Malaria (EFO_0001068), Breast Neoplasm (EFO_0003869), Prostate Cancer (MONDO_0008315), Mantle Cell Lymphoma (EFO_1001469), Lymphoma (EFO_0000574), Mycosis Fungoides (EFO_1001051), Diffuse Large B-Cell Lymphoma (EFO_0000403), Sepsis (HP_0100806), Neoplasm Of Mature B-Cells (EFO_0000096), Renal Cell Carcinoma (EFO_0000681), Waldenstrom Macroglobulinemia (EFO_0009441), Carcinoma (EFO_0000313), Cutaneous T-Cell Lymphoma (EFO_0002913), Malt Lymphoma (EFO_0000191), Follicular Lymphoma (MONDO_0018906), Hiv Infection (EFO_0000764), Non-Small Cell Lung Carcinoma (EFO_0003060), Melanoma (EFO_0000756), Esophageal Cancer (MONDO_0007576)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'TLR9 (ENSG00000239732)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.769 | Q17 | What gene does the drug Metipranolol Hydrochloride target? | The drug Metipranolol Hydrochloride targets 2 genes: ADRB1 and ADRB2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%metipranolol hydrochloride%" OR LOWER(tradeNames_string) LIKE "%metipranolol hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%metipranolol hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4267', 'drugName': 'Metipranolol Hydrochloride', 'tradeNames_string': 'Metipranolol, Optipranolol', 'drugSynonyms_string': 'Betamann, Metipranolol hcl, Metipranolol hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1989, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252), ADRB1 (ENSG00000043591)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4268', 'drugName': 'Metipranolol Hydrochloride', 'tradeNames_string': 'Metipranolol, Optipranolol', 'drugSynonyms_string': 'Betamann, Metipranolol hcl, Metipranolol hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1989, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252), ADRB1 (ENSG00000043591)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.998 | Q17 | What gene does the drug Glasdegib target? | The drug Glasdegib targets the gene SMO. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%glasdegib%" OR LOWER(tradeNames_string) LIKE "%glasdegib%" OR LOWER(drugSynonyms_string) LIKE "%glasdegib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1242', 'drugName': 'Glasdegib', 'tradeNames_string': '', 'drugSynonyms_string': 'Glasdegib, PF-04449913, PF-4449913', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Neoplasm (EFO_0000616), Soft Tissue Sarcoma (EFO_1001968), Acute Myeloid Leukemia (EFO_0000222), Glioblastoma Multiforme (EFO_0000519), Myelodysplastic Syndrome (EFO_0000198)', 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SMO (ENSG00000128602)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2876', 'drugName': 'Glasdegib Maleate', 'tradeNames_string': 'Daurismo', 'drugSynonyms_string': 'Glasdegib maleate, PF-04449913 MALEATE', 'linkedDiseasesDrug_string': 'Acute Myeloid Leukemia (EFO_0000222)', 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SMO (ENSG00000128602)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.394 | Q17 | What gene does the drug Bromazepam target? | The drug Bromazepam targets the gene GABRA2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bromazepam%" OR LOWER(tradeNames_string) LIKE "%bromazepam%" OR LOWER(drugSynonyms_string) LIKE "%bromazepam%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2148', 'drugName': 'Bromazepam', 'tradeNames_string': 'Lectopam, Lexotan', 'drugSynonyms_string': 'Bromazepam, Bromazepam civ, Lexatin, Lexotanil, NSC-140669, RO 5-3350, RO-5-3350', 'linkedDiseasesDrug_string': 'Anxiety (EFO_0005230), Depressive Disorder (MONDO_0002050), Schizophrenia (MONDO_0005090), Dementia (HP_0000726)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA2 (ENSG00000151834)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.238 | Q17 | What gene does the drug Isosorbide Dinitrate target? | The drug Isosorbide Dinitrate targets 4 genes: GUCY1A1, GUCY1B2, GUCY1A2 and GUCY1B1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%isosorbide dinitrate%" OR LOWER(tradeNames_string) LIKE "%isosorbide dinitrate%" OR LOWER(drugSynonyms_string) LIKE "%isosorbide dinitrate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1011', 'drugName': 'Isosorbide Dinitrate', 'tradeNames_string': 'Angitak, Carvasin, Cedocard, Cedocard ret, Cedocard-10, Cedocard-20, Cedocard-40, Cedocard-5, Dilatrate, Dilatrate-sr, Imtack, Iso mack, Isocard, Isoket 10, Isoket 20, Isoket 5, Isoket ret 20, Isoket ret 40, Isordil, Isordil tembids, Isosorbide dinitrate, Jeridin, Soni-slo, Sorbichew, Sorbid sa, Sorbid-20 sa, Sorbid-40 sa, Sorbidilat, Sorbitrate, Vascardin', 'drugSynonyms_string': 'C01DA08, Diluted isosorbide dinitrate, Diluted isosorbide dinitrate rs, Diluted-isosorbide dinitrate, Isomannide dinitrate, Isomannide-dinitrate, Isosorbide dinitrate, Isosorbide dinitrate, diluted, Isosorbide dinitrate, diluted-, Isosorbidi dinitras dilutes, Isosorbidi dinitras dilutus, NSC-80038, Sorbide nitrate', 'linkedDiseasesDrug_string': 'Congestive Heart Failure (EFO_0000373), Coronary Artery Disease (EFO_0001645), Angina Pectoris (EFO_0003913), Hemorrhoid (EFO_0009552), Duchenne Muscular Dystrophy (MONDO_0010679), Cardiovascular Disease (EFO_0000319), Diabetic Foot (EFO_1001459), Myocardial Ischemia (EFO_1001375)', 'yearOfFirstApproval': 1986, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GUCY1B1 (ENSG00000061918), GUCY1B2 (ENSG00000123201), GUCY1A2 (ENSG00000152402), GUCY1A1 (ENSG00000164116)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_2828', 'drugName': 'Isosorbide Mononitrate', 'tradeNames_string': 'Angeze 10, Angeze 20, Angeze 40, Angeze sr 40, Angeze sr 60, Angitate, Astrodur mr, Carmil xl, Chemydur 60 xl, Cibral 10, Cibral 20, Cibral 40, Cibral xl 60, Dynamin, Dynamin xl 25, Dynamin xl 50, Elantan 10, Elantan 20, Elantan 40, Elantan la 25, Elantan la 50, Eumon 40 xl, Eumon 60 xl, Imdur, Imo la, Isib 20, Isib 40, Isib 50 xl, Isib 60 xl, Ismo, Ismo 10, Ismo 20, Ismo 40, Ismo ret, Isodur, Isodur 25 xl, Isodur 50 xl, Isosorbide mononitrate, Isotard 25 xl, Isotard 40 xl, Isotard 50 xl, Isotard 60 xl, Isotrate, Ketanodur, Mcr 50, Modisal 40 xl, Modisal 60 xl, Modisal la 25, Modisal la 50, Monigen xl 60, Monit, Monit ls, Monit sr, Monit xl 60, Mono-cedocard 10, Mono-cedocard 20, Mono-cedocard 40, Monodur, Monoket, Monomax sr 40, Monomax sr 60, Monomax xl, Monomil xl, Monosorb xl 60, Pertil ret, Phasonit la 50, Relosorb xl, Slomon xl 60, Tardisc xl, Tenkosorb, Trangina xl, Vasotrate 60 sr, Xismox xl 60, Zemon 40 xl, Zemon 60 xl, Ziotan xl', 'drugSynonyms_string': '1,1-diureidisobutane, AHR-4698, BM 22.145, BM 22.145IS 5-MNAHR-4698, BM-22-145, BM-22.145, BM-22145, Corangin, Diluted isosorbide mononitrate, IS 5-MN, IS-5-MN, IS-5MN, Iso-5-mononitrate, Isobutyldiurea, Isobutylenediurea, Isosorbide 5-mononitrate, Isosorbide 5-nitrate, Isosorbide dinitrate isosorbide-5-mononitrate, Isosorbide mononitrate, Isosorbide-5-mononitrate, Monocord, NSC-758619', 'linkedDiseasesDrug_string': 'Premature Rupture Of Membranes (HP_0001788), Coronary Artery Disease (EFO_0001645), Angina Pectoris (EFO_0003913), Anal Fissure (HP_0012390), Stroke (EFO_0000712), Heart Failure (EFO_0003144), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Vascular Disease (EFO_0004264), Oligohydramnios (EFO_0007401), Pregnancy (EFO_0002950)', 'yearOfFirstApproval': 1991, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GUCY1B1 (ENSG00000061918), GUCY1B2 (ENSG00000123201), GUCY1A2 (ENSG00000152402), GUCY1A1 (ENSG00000164116)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1508 | Q17 | What gene does the drug Nebivolol Hydrochloride target? | The drug Nebivolol Hydrochloride targets 2 genes: ADRB2 and ADRB1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nebivolol hydrochloride%" OR LOWER(tradeNames_string) LIKE "%nebivolol hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%nebivolol hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6025', 'drugName': 'Nebivolol Hydrochloride', 'tradeNames_string': 'Bystolic, Nebivolol hydrochloride', 'drugSynonyms_string': 'Nebivolol hcl, Nebivolol hydrochloride, R-067555, R067555, RO67555', 'linkedDiseasesDrug_string': 'Stroke (EFO_0000712), Hypertension (EFO_0000537)', 'yearOfFirstApproval': 2007, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_6026', 'drugName': 'Nebivolol Hydrochloride', 'tradeNames_string': 'Bystolic, Nebivolol hydrochloride', 'drugSynonyms_string': 'Nebivolol hcl, Nebivolol hydrochloride, R-067555, R067555, RO67555', 'linkedDiseasesDrug_string': 'Stroke (EFO_0000712), Hypertension (EFO_0000537)', 'yearOfFirstApproval': 2007, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.270 | Q17 | What gene does the drug Fluticasone Furoate target? | The drug Fluticasone Furoate targets the gene NR3C1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fluticasone furoate%" OR LOWER(tradeNames_string) LIKE "%fluticasone furoate%" OR LOWER(drugSynonyms_string) LIKE "%fluticasone furoate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1921', 'drugName': 'Fluticasone Furoate', 'tradeNames_string': 'Arnuity ellipta, Avamys, Flonase sensimist allergy relief, Relvar ellipta, Trelegy ellipta, Veramyst', 'drugSynonyms_string': 'Allermist, Ennhale, Fluticasone furoate, Furamist, GSK 685 698, GSK-685968, GSK685968, GW-685698X, GW685698X', 'linkedDiseasesDrug_string': 'Asthma (MONDO_0004979), Rhinitis, Allergic, Perennial (EFO_1001417), Seasonal Allergic Rhinitis (EFO_0003956), Chronic Obstructive Pulmonary Disease (EFO_0000341), Airway Obstruction (HP_0006536), Vasomotor Rhinitis (EFO_0007533), Allergic Rhinitis (EFO_0005854), Nasal Congestion (HP_0001742), Rhinitis (EFO_0008521)', 'yearOfFirstApproval': 2007, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1187 | Q17 | What gene does the drug Hexocyclium Methylsulfate target? | The drug Hexocyclium Methylsulfate targets 2 genes: CHRM3 and CHRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%hexocyclium methylsulfate%" OR LOWER(tradeNames_string) LIKE "%hexocyclium methylsulfate%" OR LOWER(drugSynonyms_string) LIKE "%hexocyclium methylsulfate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2265', 'drugName': 'Hexocyclium Methylsulfate', 'tradeNames_string': 'Tral', 'drugSynonyms_string': 'Hexocyclium methyl sulfate, Hexocyclium methylsulfate, Hexocyclium methylsulphate, Hexocyclium metilsulfate, Hexocyclium metilsulphate, NSC-30256', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM1 (ENSG00000168539), CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2266', 'drugName': 'Hexocyclium Methylsulfate', 'tradeNames_string': 'Tral', 'drugSynonyms_string': 'Hexocyclium methyl sulfate, Hexocyclium methylsulfate, Hexocyclium methylsulphate, Hexocyclium metilsulfate, Hexocyclium metilsulphate, NSC-30256', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM1 (ENSG00000168539), CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.120 | Q17 | What gene does the drug Liatermin target? | The drug Liatermin is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene GFRA1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%liatermin%" OR LOWER(tradeNames_string) LIKE "%liatermin%" OR LOWER(drugSynonyms_string) LIKE "%liatermin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4217', 'drugName': 'Liatermin', 'tradeNames_string': '', 'drugSynonyms_string': 'Gdnf liatermin, Liatermin, R-methugdnf', 'linkedDiseasesDrug_string': 'Parkinson Disease (MONDO_0005180)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'GFRA1 (ENSG00000151892)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1607 | Q17 | What gene does the drug Naloxone target? | The drug Naloxone targets 3 genes: OPRK1, OPRM1 and OPRD1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%naloxone%" OR LOWER(tradeNames_string) LIKE "%naloxone%" OR LOWER(drugSynonyms_string) LIKE "%naloxone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3927', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_string': 'Evzio, Evzio (autoinjector), Kloxxado, Nalone, Naloxone, Naloxone hydrochloride, Naloxone hydrochloride (autoinjector), Narcan, Narcan neonatal, Narconil, Prenoxad, Zimhi', 'drugSynonyms_string': 'Anhydrous naloxone hydrochloride, EN-15304, NIH 7890, NSC-757109, Naloxone hcl, Naloxone hydrochloride, Naloxone hydrochloride anhydrous, Naloxoni hydrochloridum anhydrous, Narcanti', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Intestinal Obstruction (MONDO_0004565), Septic Shock (EFO_0006834), Pain (EFO_0003843), Constipation (HP_0002019), Opioid Dependence (EFO_0005611), Gambling Behaviour (EFO_0004699)', 'yearOfFirstApproval': 1971, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_5202', 'drugName': 'Naloxone', 'tradeNames_string': 'Nalone, Narcan, Narcanti', 'drugSynonyms_string': 'Dbl naloxone, NSC-70413, Naloxone, Suboxone', 'linkedDiseasesDrug_string': "Sezary'S Disease (EFO_1000785), Cancer (MONDO_0004992), Pain (EFO_0003843), Obesity (EFO_0001073), Irritable Bowel Syndrome (EFO_0000555), Hypogonadotropic Hypogonadism (MONDO_0018555), Eating Disorder (EFO_0005203), Hepatitis C Virus Infection (EFO_0003047), Morphine Dependence (EFO_0005612), Substance Withdrawal Syndrome (EFO_0005800), Septic Shock (EFO_0006834), Neuropathic Pain (EFO_0005762), Parkinson Disease (MONDO_0005180), Mycosis Fungoides (EFO_1001051), Epilepsy (EFO_0000474), Pruritus (HP_0000989), Heroin Dependence (EFO_0004240), Restless Legs Syndrome (EFO_0004270), Drug Dependence (EFO_0003890), Diabetic Polyneuropathy (MONDO_0001583), Intestinal Obstruction (MONDO_0004565), Constipation (HP_0002019), Opioid Dependence (EFO_0005611), Gambling Behaviour (EFO_0004699), Unipolar Depression (EFO_0003761), Opioid Use Disorder (EFO_0010702), Osteoarthritis (MONDO_0005178), Chronic Pain (HP_0012532), Low Back Pain (HP_0003419), Type 1 Diabetes Mellitus (MONDO_0005147)", 'yearOfFirstApproval': 1971, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.680 | Q17 | What gene does the drug Torcetrapib target? | The drug Torcetrapib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CETP. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%torcetrapib%" OR LOWER(tradeNames_string) LIKE "%torcetrapib%" OR LOWER(drugSynonyms_string) LIKE "%torcetrapib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1801', 'drugName': 'Torcetrapib', 'tradeNames_string': '', 'drugSynonyms_string': 'CP-529,414, CP-529414, Torcetrapib', 'linkedDiseasesDrug_string': 'Hyperlipidemia (MONDO_0021187), Hyperlipoproteinemia Type 3 (MONDO_0018473), Coronary Artery Disease (EFO_0001645), Hypertriglyceridemia (EFO_0004211), Combined Hyperlipidemia (Orphanet_79211), Familial Hypercholesterolemia (EFO_0004911), Hypercholesterolemia (HP_0003124), Disorder Of Lipid Metabolism (Orphanet_309005), Hyperlipoproteinemia Type 4 (Orphanet_413)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'CETP (ENSG00000087237)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.252 | Q17 | What gene does the drug Cinacalcet Hydrochloride target? | The drug Cinacalcet Hydrochloride targets the gene CASR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cinacalcet hydrochloride%" OR LOWER(tradeNames_string) LIKE "%cinacalcet hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%cinacalcet hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_841', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_string': 'Mimpara, Sensipar', 'drugSynonyms_string': 'AMG-073, AMG-073 HCL, AMG073 HCL, AMG073 HYDROCHLORIDE, Cinacalcet hcl, Cinacalcet hydrochloride', 'linkedDiseasesDrug_string': 'Chronic Kidney Disease (EFO_0003884), Secondary Hyperparathyroidism (EFO_1001173), Parathyroid Gland Carcinoma (EFO_1000456), Carcinoma (EFO_0000313), Prostate Adenocarcinoma (EFO_0000673)', 'yearOfFirstApproval': 2004, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CASR (ENSG00000036828)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1958 | Q17 | What gene does the drug Rxdx-103 target? | The drug Rxdx-103 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CDC7. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%rxdx-103%" OR LOWER(tradeNames_string) LIKE "%rxdx-103%" OR LOWER(drugSynonyms_string) LIKE "%rxdx-103%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2939', 'drugName': 'Rxdx-103', 'tradeNames_string': '', 'drugSynonyms_string': 'Rxdx-103', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'CDC7 (ENSG00000097046)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1995 | Q17 | What gene does the drug Corticotropin Zinc Hydroxide target? | The drug Corticotropin Zinc Hydroxide targets the gene MC2R. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%corticotropin zinc hydroxide%" OR LOWER(tradeNames_string) LIKE "%corticotropin zinc hydroxide%" OR LOWER(drugSynonyms_string) LIKE "%corticotropin zinc hydroxide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_205', 'drugName': 'Corticotropin Zinc Hydroxide', 'tradeNames_string': 'Cortrophin zinc acth, Cortrophin-zinc', 'drugSynonyms_string': 'Corticotrophin zinc hydroxide, Corticotropin zinc hydroxide, Corticotropin-zinc hydroxide', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1955, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MC2R (ENSG00000185231)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.97 | Q17 | What gene does the drug Rasagiline Mesylate target? | The drug Rasagiline Mesylate targets the gene MAOB. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%rasagiline mesylate%" OR LOWER(tradeNames_string) LIKE "%rasagiline mesylate%" OR LOWER(drugSynonyms_string) LIKE "%rasagiline mesylate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4089', 'drugName': 'Rasagiline Mesylate', 'tradeNames_string': 'Azilect, Rasagiline mesylate', 'drugSynonyms_string': 'Agilect, Azilect, Rasagiline (as mesilate), Rasagiline mesilate, Rasagiline mesylate, Rasagline ratiopharm, TVP-1012', 'linkedDiseasesDrug_string': 'Multiple System Atrophy (EFO_1001050), Parkinson Disease (MONDO_0005180)', 'yearOfFirstApproval': 2006, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MAOB (ENSG00000069535)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.34 | Q17 | What gene does the drug Escitalopram target? | The drug Escitalopram targets the gene SLC6A4. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%escitalopram%" OR LOWER(tradeNames_string) LIKE "%escitalopram%" OR LOWER(drugSynonyms_string) LIKE "%escitalopram%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4125', 'drugName': 'Escitalopram Oxalate', 'tradeNames_string': 'Escitalopram oxalate, Lexapro', 'drugSynonyms_string': 'Citalopram oxalate, (s)-, Escitalopram (as oxalate), Escitalopram oxalate, LU 26-054-0, LU-26-054-0, LU-26-054-O, NSC-758934', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Anxiety Disorder (EFO_0006788), Generalized Anxiety Disorder (EFO_1001892), Panic Disorder (EFO_0004262), Major Depressive Disorder (MONDO_0002009), Depressive Disorder (MONDO_0002050), Spinal Cord Injury (EFO_1001919)', 'yearOfFirstApproval': 2002, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_767', 'drugName': 'Escitalopram', 'tradeNames_string': 'Cipralex', 'drugSynonyms_string': 'Escitalopram, Esertia, Esitol, LU-26-054', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Alzheimer Disease (MONDO_0004975), Pulmonary Hypertension (MONDO_0005149), Substance Abuse (MONDO_0002491), Bipolar I Disorder (EFO_0009963), Anxiety Disorder (EFO_0006788), Panic Disorder (EFO_0004262), Gastrointestinal Disease (EFO_0010282), Hepatitis C Virus Infection (EFO_0003047), Spinal Cord Injury (EFO_1001919), Post-Traumatic Stress Disorder (EFO_0001358), Aphasia (HP_0002381), Dementia (HP_0000726), Anxiety (EFO_0005230), Fibromyalgia (EFO_0005687), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Cocaine Dependence (EFO_0002610), Drug Dependence (EFO_0003890), Obsessive-Compulsive Disorder (EFO_0004242), Borderline Personality Disorder (HP_0012076), Stroke (EFO_0000712), Generalized Anxiety Disorder (EFO_1001892), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Rheumatoid Arthritis (EFO_0000685), Carcinoma (EFO_0000313), Social Anxiety Disorder (EFO_1001917), Unipolar Depression (EFO_0003761), Chronic Kidney Disease (EFO_0003884), Major Depressive Disorder (MONDO_0002009), Phobic Disorder (EFO_1001908), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 2002, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1465 | Q17 | What gene does the drug Desonide target? | The drug Desonide targets the gene NR3C1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%desonide%" OR LOWER(tradeNames_string) LIKE "%desonide%" OR LOWER(drugSynonyms_string) LIKE "%desonide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3983', 'drugName': 'Desonide', 'tradeNames_string': 'Desonate, Desonide, Desowen, Tridesilon, Verdeso', 'drugSynonyms_string': 'D-2083, D2083, Desonate, Desonide, NSC-759226', 'linkedDiseasesDrug_string': 'Eye Inflammation (EFO_0005752), Skin Disease (EFO_0000701), Atopic Eczema (EFO_0000274)', 'yearOfFirstApproval': 1972, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3329', 'drugName': 'Budesonide', 'tradeNames_string': 'Aircort, Budeflam aquanase, Budelin novolizer, Budenofalk, Budesonide, Cortiment, Duoresp spiromax, Entocort, Entocort cr, Entocort ec, Ortikos, Preferid, Pulmaxan, Pulmicort, Pulmicort flexhaler, Pulmicort l.s., Pulmicort respules, Rhinocort, Rhinocort allergy, Rhinocort aqua, Rhinocort aqua 64, Symbicort, Tarpeyo, Uceris', 'drugSynonyms_string': 'Budesonide, MAP-0010, MAP0010, NSC-757788, R01AD05, S-1320', 'linkedDiseasesDrug_string': "Status Asthmaticus (EFO_0008590), Allergic Bronchopulmonary Aspergillosis (EFO_0007140), Multiple Myeloma (EFO_0001378), Esophageal Stricture (HP_0002043), Radiation Pneumonitis (EFO_1001411), Graft Versus Host Disease (MONDO_0013730), Covid-19 (MONDO_0100096), Iga Glomerulonephritis (EFO_0004194), Lymphocytic Colitis (EFO_1001294), Allergic Rhinitis (EFO_0005854), Ulcerative Colitis (EFO_0000729), Primary Biliary Cirrhosis (EFO_1001486), Bronchiolitis Obliterans (EFO_0007183), Proctitis (EFO_0005628), Diarrhea (HP_0002014), Collagenous Colitis (EFO_1001293), Crohn'S Disease (EFO_0000384), Breast Cancer (MONDO_0007254), Seasonal Allergic Rhinitis (EFO_0003956), Acute Respiratory Distress Syndrome (EFO_1000637), Acute Graft Vs. Host Disease (EFO_0004599), Emphysema (EFO_0000464), Nasal Cavity Polyp (EFO_1000391), Sinusitis (EFO_0007486), Asthma (MONDO_0004979), Respiratory System Disease (EFO_0000684), Ulcerative Proctosigmoiditis (EFO_1001223), Rhinitis, Allergic, Perennial (EFO_1001417), Chronic Obstructive Pulmonary Disease (EFO_0000341), Airway Obstruction (HP_0006536), Obstructive Sleep Apnea (EFO_0003918), Nasal Congestion (HP_0001742), Malnutrition (EFO_0008572), Altitude Sickness (EFO_1000782), Allergic Disease (MONDO_0005271), Microscopic Colitis (EFO_1001295), Sclerosing Cholangitis (EFO_0004268), Chronic Bronchitis (EFO_0006505), Lung Cancer (MONDO_0008903), Autoimmune Hepatitis (EFO_0005676), Melanoma (EFO_0000756), Eosinophilic Esophagitis (EFO_0004232), Bronchopulmonary Dysplasia (MONDO_0019091), Severe Acute Respiratory Syndrome (EFO_0000694), Snoring (HP_0025267)", 'yearOfFirstApproval': 1994, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1668 | Q17 | What gene does the drug Propanidid target? | The drug Propanidid targets 2 genes: ACHE and BCHE. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%propanidid%" OR LOWER(tradeNames_string) LIKE "%propanidid%" OR LOWER(drugSynonyms_string) LIKE "%propanidid%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3732', 'drugName': 'Propanidid', 'tradeNames_string': 'Epontol', 'drugSynonyms_string': 'BAYER 1420, BAYER-1420, FBA 1420, FBA-1420, Propanidid, TH-2180, WH 5668, WH-5668', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACHE (ENSG00000087085), BCHE (ENSG00000114200)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3733', 'drugName': 'Propanidid', 'tradeNames_string': 'Epontol', 'drugSynonyms_string': 'BAYER 1420, BAYER-1420, FBA 1420, FBA-1420, Propanidid, TH-2180, WH 5668, WH-5668', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACHE (ENSG00000087085), BCHE (ENSG00000114200)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.454 | Q17 | What gene does the drug Topiramate target? | The drug Topiramate targets 37 genes: CA4, SCN9A, SCN7A, GRIK2, SCN10A, GRIA4, SCN4A, GRIA2, GABRG2, GABRA4, SCN8A, SCN2A, GABRB3, GABRA2, GABRA1, SCN3A, GABRE, GABRP, GRIA3, GABRG3, SCN5A, GABRB1, GABRA6, SCN1A, GABRA5, GABRQ, GABRD, GABRA3, CA2, SCN11A, GRIK1, GABRB2, GRIA1, GABRG1, GRIK4, GRIK5 and GRIK3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%topiramate%" OR LOWER(tradeNames_string) LIKE "%topiramate%" OR LOWER(drugSynonyms_string) LIKE "%topiramate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1597', 'drugName': 'Topiramate', 'tradeNames_string': 'Epitomax, Eprontia, Qudexy xr, Topamax, Topamax sprinkle, Topiramate, Trokendi xr', 'drugSynonyms_string': '(-)-topiramate, Epitoma, Eprontia, MCN-4853, Qudexy, RWJ-17021, RWJ-17021-000, Sincronil, Topamac, Topimax, Topina, Topiramate, Topomax, USL-255, USL255', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Hyperlipidemia (MONDO_0021187), Hypertriglyceridemia (EFO_0004211), Multiple Sclerosis (MONDO_0005301), Liver Disease (EFO_0001421), Migraine Disorder (MONDO_0005277), Tourette Syndrome (EFO_0004895), Obesity (EFO_0001073), Pain (EFO_0003843), Lennox-Gastaut Syndrome (MONDO_0016532), Cannabis Dependence (EFO_0007191), Prader-Willi Syndrome (MONDO_0008300), Eating Disorder (EFO_0005203), Deafness (EFO_0001063), Post-Traumatic Stress Disorder (EFO_0001358), Alcohol Abuse (MONDO_0002046), Sciatica (HP_0011868), Headache (HP_0002315), Nicotine Dependence (EFO_0003768), Hypertension (EFO_0000537), Dementia (HP_0000726), Parkinson Disease (MONDO_0005180), Anxiety (EFO_0005230), Brain Ischemia (MONDO_0005299), Epilepsy With Generalized Tonic-Clonic Seizures (EFO_0007262), Partial Epilepsy (EFO_0004263), Cocaine Dependence (EFO_0002610), Epilepsy (EFO_0000474), Seizure (HP_0001250), Alcohol Drinking (EFO_0004329), Methamphetamine Dependence (EFO_0004701), Binge Eating (EFO_0005924), Obsessive-Compulsive Disorder (EFO_0004242), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Alcohol Dependence (MONDO_0007079), Congenital Heart Disease (EFO_0005207), Gambling Behaviour (EFO_0004699), Smoking Cessation (EFO_0004319), Cognitive Impairment (HP_0100543), Essential Tremor (EFO_0003108), Metabolic Syndrome (EFO_0000195), Bulimia Nervosa (EFO_0005204), Type 2 Diabetes Mellitus (MONDO_0005148), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIK1 (ENSG00000171189), GRIK5 (ENSG00000105737), GRIK4 (ENSG00000149403), GRIK2 (ENSG00000164418), GRIK3 (ENSG00000163873), CA4 (ENSG00000167434), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), CA2 (ENSG00000104267), GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511)', 'numberLinkedTargets': 37}, {'UUID': 'DrugGeneTargets_v2_1593', 'drugName': 'Topiramate', 'tradeNames_string': 'Epitomax, Eprontia, Qudexy xr, Topamax, Topamax sprinkle, Topiramate, Trokendi xr', 'drugSynonyms_string': '(-)-topiramate, Epitoma, Eprontia, MCN-4853, Qudexy, RWJ-17021, RWJ-17021-000, Sincronil, Topamac, Topimax, Topina, Topiramate, Topomax, USL-255, USL255', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Hyperlipidemia (MONDO_0021187), Hypertriglyceridemia (EFO_0004211), Multiple Sclerosis (MONDO_0005301), Liver Disease (EFO_0001421), Migraine Disorder (MONDO_0005277), Tourette Syndrome (EFO_0004895), Obesity (EFO_0001073), Pain (EFO_0003843), Lennox-Gastaut Syndrome (MONDO_0016532), Cannabis Dependence (EFO_0007191), Prader-Willi Syndrome (MONDO_0008300), Eating Disorder (EFO_0005203), Deafness (EFO_0001063), Post-Traumatic Stress Disorder (EFO_0001358), Alcohol Abuse (MONDO_0002046), Sciatica (HP_0011868), Headache (HP_0002315), Nicotine Dependence (EFO_0003768), Hypertension (EFO_0000537), Dementia (HP_0000726), Parkinson Disease (MONDO_0005180), Anxiety (EFO_0005230), Brain Ischemia (MONDO_0005299), Epilepsy With Generalized Tonic-Clonic Seizures (EFO_0007262), Partial Epilepsy (EFO_0004263), Cocaine Dependence (EFO_0002610), Epilepsy (EFO_0000474), Seizure (HP_0001250), Alcohol Drinking (EFO_0004329), Methamphetamine Dependence (EFO_0004701), Binge Eating (EFO_0005924), Obsessive-Compulsive Disorder (EFO_0004242), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Alcohol Dependence (MONDO_0007079), Congenital Heart Disease (EFO_0005207), Gambling Behaviour (EFO_0004699), Smoking Cessation (EFO_0004319), Cognitive Impairment (HP_0100543), Essential Tremor (EFO_0003108), Metabolic Syndrome (EFO_0000195), Bulimia Nervosa (EFO_0005204), Type 2 Diabetes Mellitus (MONDO_0005148), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIK1 (ENSG00000171189), GRIK5 (ENSG00000105737), GRIK4 (ENSG00000149403), GRIK2 (ENSG00000164418), GRIK3 (ENSG00000163873), CA4 (ENSG00000167434), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), CA2 (ENSG00000104267), GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511)', 'numberLinkedTargets': 37}, {'UUID': 'DrugGeneTargets_v2_1592', 'drugName': 'Topiramate', 'tradeNames_string': 'Epitomax, Eprontia, Qudexy xr, Topamax, Topamax sprinkle, Topiramate, Trokendi xr', 'drugSynonyms_string': '(-)-topiramate, Epitoma, Eprontia, MCN-4853, Qudexy, RWJ-17021, RWJ-17021-000, Sincronil, Topamac, Topimax, Topina, Topiramate, Topomax, USL-255, USL255', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Hyperlipidemia (MONDO_0021187), Hypertriglyceridemia (EFO_0004211), Multiple Sclerosis (MONDO_0005301), Liver Disease (EFO_0001421), Migraine Disorder (MONDO_0005277), Tourette Syndrome (EFO_0004895), Obesity (EFO_0001073), Pain (EFO_0003843), Lennox-Gastaut Syndrome (MONDO_0016532), Cannabis Dependence (EFO_0007191), Prader-Willi Syndrome (MONDO_0008300), Eating Disorder (EFO_0005203), Deafness (EFO_0001063), Post-Traumatic Stress Disorder (EFO_0001358), Alcohol Abuse (MONDO_0002046), Sciatica (HP_0011868), Headache (HP_0002315), Nicotine Dependence (EFO_0003768), Hypertension (EFO_0000537), Dementia (HP_0000726), Parkinson Disease (MONDO_0005180), Anxiety (EFO_0005230), Brain Ischemia (MONDO_0005299), Epilepsy With Generalized Tonic-Clonic Seizures (EFO_0007262), Partial Epilepsy (EFO_0004263), Cocaine Dependence (EFO_0002610), Epilepsy (EFO_0000474), Seizure (HP_0001250), Alcohol Drinking (EFO_0004329), Methamphetamine Dependence (EFO_0004701), Binge Eating (EFO_0005924), Obsessive-Compulsive Disorder (EFO_0004242), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Alcohol Dependence (MONDO_0007079), Congenital Heart Disease (EFO_0005207), Gambling Behaviour (EFO_0004699), Smoking Cessation (EFO_0004319), Cognitive Impairment (HP_0100543), Essential Tremor (EFO_0003108), Metabolic Syndrome (EFO_0000195), Bulimia Nervosa (EFO_0005204), Type 2 Diabetes Mellitus (MONDO_0005148), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIK1 (ENSG00000171189), GRIK5 (ENSG00000105737), GRIK4 (ENSG00000149403), GRIK2 (ENSG00000164418), GRIK3 (ENSG00000163873), CA4 (ENSG00000167434), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), CA2 (ENSG00000104267), GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511)', 'numberLinkedTargets': 37}, {'UUID': 'DrugGeneTargets_v2_1595', 'drugName': 'Topiramate', 'tradeNames_string': 'Epitomax, Eprontia, Qudexy xr, Topamax, Topamax sprinkle, Topiramate, Trokendi xr', 'drugSynonyms_string': '(-)-topiramate, Epitoma, Eprontia, MCN-4853, Qudexy, RWJ-17021, RWJ-17021-000, Sincronil, Topamac, Topimax, Topina, Topiramate, Topomax, USL-255, USL255', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Hyperlipidemia (MONDO_0021187), Hypertriglyceridemia (EFO_0004211), Multiple Sclerosis (MONDO_0005301), Liver Disease (EFO_0001421), Migraine Disorder (MONDO_0005277), Tourette Syndrome (EFO_0004895), Obesity (EFO_0001073), Pain (EFO_0003843), Lennox-Gastaut Syndrome (MONDO_0016532), Cannabis Dependence (EFO_0007191), Prader-Willi Syndrome (MONDO_0008300), Eating Disorder (EFO_0005203), Deafness (EFO_0001063), Post-Traumatic Stress Disorder (EFO_0001358), Alcohol Abuse (MONDO_0002046), Sciatica (HP_0011868), Headache (HP_0002315), Nicotine Dependence (EFO_0003768), Hypertension (EFO_0000537), Dementia (HP_0000726), Parkinson Disease (MONDO_0005180), Anxiety (EFO_0005230), Brain Ischemia (MONDO_0005299), Epilepsy With Generalized Tonic-Clonic Seizures (EFO_0007262), Partial Epilepsy (EFO_0004263), Cocaine Dependence (EFO_0002610), Epilepsy (EFO_0000474), Seizure (HP_0001250), Alcohol Drinking (EFO_0004329), Methamphetamine Dependence (EFO_0004701), Binge Eating (EFO_0005924), Obsessive-Compulsive Disorder (EFO_0004242), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Alcohol Dependence (MONDO_0007079), Congenital Heart Disease (EFO_0005207), Gambling Behaviour (EFO_0004699), Smoking Cessation (EFO_0004319), Cognitive Impairment (HP_0100543), Essential Tremor (EFO_0003108), Metabolic Syndrome (EFO_0000195), Bulimia Nervosa (EFO_0005204), Type 2 Diabetes Mellitus (MONDO_0005148), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIK1 (ENSG00000171189), GRIK5 (ENSG00000105737), GRIK4 (ENSG00000149403), GRIK2 (ENSG00000164418), GRIK3 (ENSG00000163873), CA4 (ENSG00000167434), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), CA2 (ENSG00000104267), GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511)', 'numberLinkedTargets': 37}, {'UUID': 'DrugGeneTargets_v2_1596', 'drugName': 'Topiramate', 'tradeNames_string': 'Epitomax, Eprontia, Qudexy xr, Topamax, Topamax sprinkle, Topiramate, Trokendi xr', 'drugSynonyms_string': '(-)-topiramate, Epitoma, Eprontia, MCN-4853, Qudexy, RWJ-17021, RWJ-17021-000, Sincronil, Topamac, Topimax, Topina, Topiramate, Topomax, USL-255, USL255', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Hyperlipidemia (MONDO_0021187), Hypertriglyceridemia (EFO_0004211), Multiple Sclerosis (MONDO_0005301), Liver Disease (EFO_0001421), Migraine Disorder (MONDO_0005277), Tourette Syndrome (EFO_0004895), Obesity (EFO_0001073), Pain (EFO_0003843), Lennox-Gastaut Syndrome (MONDO_0016532), Cannabis Dependence (EFO_0007191), Prader-Willi Syndrome (MONDO_0008300), Eating Disorder (EFO_0005203), Deafness (EFO_0001063), Post-Traumatic Stress Disorder (EFO_0001358), Alcohol Abuse (MONDO_0002046), Sciatica (HP_0011868), Headache (HP_0002315), Nicotine Dependence (EFO_0003768), Hypertension (EFO_0000537), Dementia (HP_0000726), Parkinson Disease (MONDO_0005180), Anxiety (EFO_0005230), Brain Ischemia (MONDO_0005299), Epilepsy With Generalized Tonic-Clonic Seizures (EFO_0007262), Partial Epilepsy (EFO_0004263), Cocaine Dependence (EFO_0002610), Epilepsy (EFO_0000474), Seizure (HP_0001250), Alcohol Drinking (EFO_0004329), Methamphetamine Dependence (EFO_0004701), Binge Eating (EFO_0005924), Obsessive-Compulsive Disorder (EFO_0004242), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Alcohol Dependence (MONDO_0007079), Congenital Heart Disease (EFO_0005207), Gambling Behaviour (EFO_0004699), Smoking Cessation (EFO_0004319), Cognitive Impairment (HP_0100543), Essential Tremor (EFO_0003108), Metabolic Syndrome (EFO_0000195), Bulimia Nervosa (EFO_0005204), Type 2 Diabetes Mellitus (MONDO_0005148), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIK1 (ENSG00000171189), GRIK5 (ENSG00000105737), GRIK4 (ENSG00000149403), GRIK2 (ENSG00000164418), GRIK3 (ENSG00000163873), CA4 (ENSG00000167434), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), CA2 (ENSG00000104267), GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511)', 'numberLinkedTargets': 37}, {'UUID': 'DrugGeneTargets_v2_1594', 'drugName': 'Topiramate', 'tradeNames_string': 'Epitomax, Eprontia, Qudexy xr, Topamax, Topamax sprinkle, Topiramate, Trokendi xr', 'drugSynonyms_string': '(-)-topiramate, Epitoma, Eprontia, MCN-4853, Qudexy, RWJ-17021, RWJ-17021-000, Sincronil, Topamac, Topimax, Topina, Topiramate, Topomax, USL-255, USL255', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Hyperlipidemia (MONDO_0021187), Hypertriglyceridemia (EFO_0004211), Multiple Sclerosis (MONDO_0005301), Liver Disease (EFO_0001421), Migraine Disorder (MONDO_0005277), Tourette Syndrome (EFO_0004895), Obesity (EFO_0001073), Pain (EFO_0003843), Lennox-Gastaut Syndrome (MONDO_0016532), Cannabis Dependence (EFO_0007191), Prader-Willi Syndrome (MONDO_0008300), Eating Disorder (EFO_0005203), Deafness (EFO_0001063), Post-Traumatic Stress Disorder (EFO_0001358), Alcohol Abuse (MONDO_0002046), Sciatica (HP_0011868), Headache (HP_0002315), Nicotine Dependence (EFO_0003768), Hypertension (EFO_0000537), Dementia (HP_0000726), Parkinson Disease (MONDO_0005180), Anxiety (EFO_0005230), Brain Ischemia (MONDO_0005299), Epilepsy With Generalized Tonic-Clonic Seizures (EFO_0007262), Partial Epilepsy (EFO_0004263), Cocaine Dependence (EFO_0002610), Epilepsy (EFO_0000474), Seizure (HP_0001250), Alcohol Drinking (EFO_0004329), Methamphetamine Dependence (EFO_0004701), Binge Eating (EFO_0005924), Obsessive-Compulsive Disorder (EFO_0004242), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Alcohol Dependence (MONDO_0007079), Congenital Heart Disease (EFO_0005207), Gambling Behaviour (EFO_0004699), Smoking Cessation (EFO_0004319), Cognitive Impairment (HP_0100543), Essential Tremor (EFO_0003108), Metabolic Syndrome (EFO_0000195), Bulimia Nervosa (EFO_0005204), Type 2 Diabetes Mellitus (MONDO_0005148), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIK1 (ENSG00000171189), GRIK5 (ENSG00000105737), GRIK4 (ENSG00000149403), GRIK2 (ENSG00000164418), GRIK3 (ENSG00000163873), CA4 (ENSG00000167434), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), CA2 (ENSG00000104267), GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511)', 'numberLinkedTargets': 37}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.723 | Q17 | What gene does the drug Pemetrexed Tromethamine target? | The drug Pemetrexed Tromethamine targets 2 genes: GART and DHFR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pemetrexed tromethamine%" OR LOWER(tradeNames_string) LIKE "%pemetrexed tromethamine%" OR LOWER(drugSynonyms_string) LIKE "%pemetrexed tromethamine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1187', 'drugName': 'Pemetrexed Tromethamine', 'tradeNames_string': '', 'drugSynonyms_string': 'Pemetrexed ditrometamol, Pemetrexed ditromethamine, Pemetrexed tromethamine, Pemetrexed tromethamine anhydrous', 'linkedDiseasesDrug_string': 'Large Cell Lung Carcinoma (EFO_0003050), Adenocarcinoma (EFO_0000228)', 'yearOfFirstApproval': 2022, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DHFR (ENSG00000228716), GART (ENSG00000159131)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1188', 'drugName': 'Pemetrexed Tromethamine', 'tradeNames_string': '', 'drugSynonyms_string': 'Pemetrexed ditrometamol, Pemetrexed ditromethamine, Pemetrexed tromethamine, Pemetrexed tromethamine anhydrous', 'linkedDiseasesDrug_string': 'Large Cell Lung Carcinoma (EFO_0003050), Adenocarcinoma (EFO_0000228)', 'yearOfFirstApproval': 2022, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DHFR (ENSG00000228716), GART (ENSG00000159131)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1189', 'drugName': 'Pemetrexed Tromethamine', 'tradeNames_string': '', 'drugSynonyms_string': 'Pemetrexed ditrometamol, Pemetrexed ditromethamine, Pemetrexed tromethamine, Pemetrexed tromethamine anhydrous', 'linkedDiseasesDrug_string': 'Large Cell Lung Carcinoma (EFO_0003050), Adenocarcinoma (EFO_0000228)', 'yearOfFirstApproval': 2022, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DHFR (ENSG00000228716), GART (ENSG00000159131)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1261 | Q17 | What gene does the drug Furosemide target? | The drug Furosemide targets the gene SLC12A1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%furosemide%" OR LOWER(tradeNames_string) LIKE "%furosemide%" OR LOWER(drugSynonyms_string) LIKE "%furosemide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2676', 'drugName': 'Furosemide', 'tradeNames_string': 'Aluzine 20, Aluzine 40, Aluzine 500, Aquamed, Disal, Diuresal, Dryptal, Froop, Frumax, Frumil, Frusemide, Frusetic, Frusid, Frusol, Furosemide, Hydroled, Lasix, Lasix ret, Rusyde, Tenkofruse', 'drugSynonyms_string': 'Frusemide, Furosemide, Furosemidum, LB-502, Logirene, Marsemide, Mirfat, NSC-269420, Oedemex', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Cancer (MONDO_0004992), Coronary Artery Disease (EFO_0001645), Essential Hypertension (MONDO_0001134), Kidney Failure (EFO_1002048), Metastatic Melanoma (EFO_0002617), Common Wart (EFO_0009662), Pulmonary Embolism (EFO_0003827), Atherosclerosis (EFO_0003914), Lung Disease (EFO_0003818), Bronchiolitis (HP_0011950), Edema (EFO_0009373), Nephrotic Syndrome (EFO_0004255), Congestive Heart Failure (EFO_0000373), Preeclampsia (EFO_0000668), Acute Lung Injury (EFO_0004610), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Acute Myocardial Infarction (EFO_0008583), Acute Myeloid Leukemia (EFO_0000222), Pulmonary Edema (EFO_1001134), Nasal Cavity Polyp (EFO_1000391), Premature Birth (EFO_0003917), Tachypnea (EFO_0009840), Actinic Keratosis (EFO_0002496), Hypercholesterolemia (HP_0003124), Hypertension, Pregnancy-Induced (MONDO_0024664), Dyspnea (HP_0002094), Chronic Kidney Disease (EFO_0003884), Leukemia (EFO_0000565), Heart Failure (EFO_0003144), Kidney Disease (EFO_0003086), Acute Kidney Injury (HP_0001919), Bronchopulmonary Dysplasia (MONDO_0019091), Type 2 Diabetes Mellitus (MONDO_0005148), Schizophrenia (MONDO_0005090), Cirrhosis Of Liver (EFO_0001422)', 'yearOfFirstApproval': 1966, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC12A1 (ENSG00000074803)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1598 | Q17 | What gene does the drug Landogrozumab target? | The drug Landogrozumab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene MSTN. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%landogrozumab%" OR LOWER(tradeNames_string) LIKE "%landogrozumab%" OR LOWER(drugSynonyms_string) LIKE "%landogrozumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1897', 'drugName': 'Landogrozumab', 'tradeNames_string': '', 'drugSynonyms_string': 'Anti-myostatin antibody, LY-2495655, LY2495655, Landogrozumab', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Cancer (MONDO_0004992), Skeletal Muscle Atrophy (HP_0003202), Muscular Disease (EFO_0002970)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'MSTN (ENSG00000138379)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1 | Q17 | What gene does the drug Sndx-5613 target? | The drug Sndx-5613 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: MEN1 and KMT2A | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sndx-5613%" OR LOWER(tradeNames_string) LIKE "%sndx-5613%" OR LOWER(drugSynonyms_string) LIKE "%sndx-5613%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3382', 'drugName': 'Sndx-5613', 'tradeNames_string': '', 'drugSynonyms_string': 'Revumenib sesquifumarate, SNDX-50613, SNDX-5613, SNDX50613, SNDX5613, Sndx 5613, Sndx-5613', 'linkedDiseasesDrug_string': 'Acute Myeloid Leukemia (EFO_0000222), Acute Lymphoblastic Leukemia (EFO_0000220)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'MEN1 (ENSG00000133895), KMT2A (ENSG00000118058)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1377 | Q17 | What gene does the drug Perindopril target? | The drug Perindopril targets the gene ACE. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%perindopril%" OR LOWER(tradeNames_string) LIKE "%perindopril%" OR LOWER(drugSynonyms_string) LIKE "%perindopril%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_252', 'drugName': 'Perindopril', 'tradeNames_string': '', 'drugSynonyms_string': 'MCN-A-2833, Perindopril, S-9490', 'linkedDiseasesDrug_string': 'Post-Traumatic Stress Disorder (EFO_0001358), Alzheimer Disease (MONDO_0004975), Methamphetamine Dependence (EFO_0004701), Coronary Artery Disease (EFO_0001645), Breast Cancer (MONDO_0007254), Substance Abuse (MONDO_0002491), Dilated Cardiomyopathy (EFO_0000407), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Essential Hypertension (MONDO_0001134), Myocardial Infarction (EFO_0000612), Childhood Cancer (EFO_1000654), Abdominal Aortic Aneurysm (EFO_0004214), Type 2 Diabetes Mellitus (MONDO_0005148), Marfan Syndrome (MONDO_0007947)', 'yearOfFirstApproval': 1993, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACE (ENSG00000159640)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1718', 'drugName': 'Perindopril Erbumine', 'tradeNames_string': 'Aceon, Coversyl, Perindopril erbumine', 'drugSynonyms_string': 'MCN-A-2833-109, NSC-758929, Perindopril erbumine, Perindopril tert-butylamine, S-9490-3', 'linkedDiseasesDrug_string': 'Coronary Artery Disease (EFO_0001645), Hypertension (EFO_0000537), Essential Hypertension (MONDO_0001134)', 'yearOfFirstApproval': 1993, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACE (ENSG00000159640)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2053', 'drugName': 'Perindopril Arginine', 'tradeNames_string': '', 'drugSynonyms_string': 'Perindopril arginine', 'linkedDiseasesDrug_string': 'Hypertension (EFO_0000537), Coronary Artery Disease (EFO_0001645), Abdominal Aortic Aneurysm (EFO_0004214), Myocardial Infarction (EFO_0000612)', 'yearOfFirstApproval': 2015, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACE (ENSG00000159640)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1110 | Q17 | What gene does the drug Volanesorsen target? | The drug Volanesorsen targets the gene APOC3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%volanesorsen%" OR LOWER(tradeNames_string) LIKE "%volanesorsen%" OR LOWER(drugSynonyms_string) LIKE "%volanesorsen%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2601', 'drugName': 'Volanesorsen', 'tradeNames_string': '', 'drugSynonyms_string': 'ISIS 304801, ISIS 304801 FREE ACID, ISIS-304801, Volanesorsen, free acid', 'linkedDiseasesDrug_string': 'Cardiovascular Disease (EFO_0000319), Hypertriglyceridemia (EFO_0004211), Familial Partial Lipodystrophy (MONDO_0020088)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'APOC3 (ENSG00000110245)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3223', 'drugName': 'Volanesorsen Sodium', 'tradeNames_string': '', 'drugSynonyms_string': 'ISIS 304801, ISIS 304801 SODIUM SALT, ISIS-304801 SODIUM, ISIS-304801 SODIUM SALT, Volanesorsen sodium, salt', 'linkedDiseasesDrug_string': 'Lipodystrophy (EFO_1000727)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'APOC3 (ENSG00000110245)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1117 | Q17 | What gene does the drug Olutasidenib target? | The drug Olutasidenib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene IDH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%olutasidenib%" OR LOWER(tradeNames_string) LIKE "%olutasidenib%" OR LOWER(drugSynonyms_string) LIKE "%olutasidenib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6331', 'drugName': 'Olutasidenib', 'tradeNames_string': '', 'drugSynonyms_string': 'FT-2102, Ft-2102, Olutasidenib', 'linkedDiseasesDrug_string': 'Myelodysplastic Syndrome (EFO_0000198), Acute Myeloid Leukemia (EFO_0000222)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'IDH1 (ENSG00000138413)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1591 | Q17 | What gene does the drug Snx 5422 target? | The drug Snx 5422 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: HSP90AA1 and HSP90AB1 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%snx 5422%" OR LOWER(tradeNames_string) LIKE "%snx 5422%" OR LOWER(drugSynonyms_string) LIKE "%snx 5422%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2883', 'drugName': 'Snx 5422', 'tradeNames_string': '', 'drugSynonyms_string': 'Pf-04929113, Pf-4929113, Snx 5422, Snx-5422', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Leukemia (EFO_0000565), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Lymphoma (EFO_0000574)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'HSP90AA1 (ENSG00000080824), HSP90AB1 (ENSG00000096384)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.85 | Q17 | What gene does the drug Sklb1028 target? | The drug Sklb1028 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 3 genes: FLT3, ABL1 and EGFR | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sklb1028%" OR LOWER(tradeNames_string) LIKE "%sklb1028%" OR LOWER(drugSynonyms_string) LIKE "%sklb1028%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5899', 'drugName': 'Sklb1028', 'tradeNames_string': '', 'drugSynonyms_string': 'Sklb1028', 'linkedDiseasesDrug_string': 'Acute Myeloid Leukemia (EFO_0000222), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'EGFR (ENSG00000146648), FLT3 (ENSG00000122025), ABL1 (ENSG00000097007)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_5900', 'drugName': 'Sklb1028', 'tradeNames_string': '', 'drugSynonyms_string': 'Sklb1028', 'linkedDiseasesDrug_string': 'Acute Myeloid Leukemia (EFO_0000222), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'EGFR (ENSG00000146648), FLT3 (ENSG00000122025), ABL1 (ENSG00000097007)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_5901', 'drugName': 'Sklb1028', 'tradeNames_string': '', 'drugSynonyms_string': 'Sklb1028', 'linkedDiseasesDrug_string': 'Acute Myeloid Leukemia (EFO_0000222), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'EGFR (ENSG00000146648), FLT3 (ENSG00000122025), ABL1 (ENSG00000097007)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1294 | Q17 | What gene does the drug Ziconotide target? | The drug Ziconotide targets the gene CACNA1B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ziconotide%" OR LOWER(tradeNames_string) LIKE "%ziconotide%" OR LOWER(drugSynonyms_string) LIKE "%ziconotide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2513', 'drugName': 'Ziconotide', 'tradeNames_string': 'Prialt', 'drugSynonyms_string': '.omega.-conotoxin m viia, SNX-111, Ziconotide', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843), Fever (HP_0001945)', 'yearOfFirstApproval': 2004, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1B (ENSG00000148408)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4779', 'drugName': 'Ziconotide Acetate', 'tradeNames_string': 'Prialt', 'drugSynonyms_string': 'Ziconotide acetate', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843), Fever (HP_0001945)', 'yearOfFirstApproval': 2004, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1B (ENSG00000148408)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.683 | Q17 | What gene does the drug Maralixibat target? | The drug Maralixibat targets the gene SLC10A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%maralixibat%" OR LOWER(tradeNames_string) LIKE "%maralixibat%" OR LOWER(drugSynonyms_string) LIKE "%maralixibat%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5944', 'drugName': 'Maralixibat Chloride', 'tradeNames_string': 'Livmarli', 'drugSynonyms_string': 'LUM-001, LUM001, Lopixibat chloride, Maralixibat chloride', 'linkedDiseasesDrug_string': 'Primary Biliary Cirrhosis (EFO_1001486), Sclerosing Cholangitis (EFO_0004268), Pruritus (HP_0000989), Alagille Syndrome (MONDO_0007318)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC10A2 (ENSG00000125255)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5835', 'drugName': 'Maralixibat', 'tradeNames_string': '', 'drugSynonyms_string': 'LUM-001 CATION, LUM001 CATION, Lopixibat, Maralixibat, Maralixibat cation', 'linkedDiseasesDrug_string': 'Biliary Atresia (MONDO_0008867), Liver Disease (EFO_0001421), Alagille Syndrome (MONDO_0007318), Sclerosing Cholangitis (EFO_0004268), Pruritus (HP_0000989), Primary Biliary Cirrhosis (EFO_1001486)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC10A2 (ENSG00000125255)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1677 | Q17 | What gene does the drug Trimethaphan Camsylate target? | The drug Trimethaphan Camsylate targets 2 genes: CHRNB4 and CHRNA3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%trimethaphan camsylate%" OR LOWER(tradeNames_string) LIKE "%trimethaphan camsylate%" OR LOWER(drugSynonyms_string) LIKE "%trimethaphan camsylate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5467', 'drugName': 'Trimethaphan Camsylate', 'tradeNames_string': 'Arfonad', 'drugSynonyms_string': 'NU-2222, Trimetaphan camsilate, Trimetaphan camsylate, Trimethaphan Camsylate, Trimethaphan camphorsulfonate, Trimethaphan camsylate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNB4 (ENSG00000117971), CHRNA3 (ENSG00000080644)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1055 | Q17 | What gene does the drug Ricolinostat target? | The drug Ricolinostat is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene HDAC6. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ricolinostat%" OR LOWER(tradeNames_string) LIKE "%ricolinostat%" OR LOWER(drugSynonyms_string) LIKE "%ricolinostat%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6353', 'drugName': 'Ricolinostat', 'tradeNames_string': '', 'drugSynonyms_string': 'ACY-1215, ACY-63, Ricolinostat', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Chronic Lymphocytic Leukemia (EFO_0000095), Diabetic Neuropathy (EFO_1000783), Peripheral Nervous System Disease (EFO_0009387), Lymphoma (EFO_0000574), Hilar Cholangiocarcinoma (EFO_1001959), Breast Carcinoma (EFO_0000305)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'HDAC6 (ENSG00000094631)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.777 | Q17 | What gene does the drug As-602868 target? | The drug As-602868 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: FLT3 and IKBKB | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%as-602868%" OR LOWER(tradeNames_string) LIKE "%as-602868%" OR LOWER(drugSynonyms_string) LIKE "%as-602868%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1504', 'drugName': 'As-602868', 'tradeNames_string': '', 'drugSynonyms_string': 'As-602868, SPC-839', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'IKBKB (ENSG00000104365), FLT3 (ENSG00000122025)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1505', 'drugName': 'As-602868', 'tradeNames_string': '', 'drugSynonyms_string': 'As-602868, SPC-839', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'IKBKB (ENSG00000104365), FLT3 (ENSG00000122025)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1289 | Q17 | What gene does the drug Upadacitinib target? | The drug Upadacitinib targets 4 genes: JAK3, TYK2, JAK1 and JAK2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%upadacitinib%" OR LOWER(tradeNames_string) LIKE "%upadacitinib%" OR LOWER(drugSynonyms_string) LIKE "%upadacitinib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4653', 'drugName': 'Upadacitinib', 'tradeNames_string': 'Rinvoq', 'drugSynonyms_string': 'ABT-494, Upadacitinib, Upadacitinib anhydrous, Upadacitinib hemihydrate, Upadacitinib hydrate', 'linkedDiseasesDrug_string': "Temporal Arteritis (EFO_1001209), Vitiligo (EFO_0004208), Crohn'S Disease (EFO_0000384), Juvenile Idiopathic Arthritis (EFO_0002609), Ankylosing Spondylitis (EFO_0003898), Atopic Eczema (EFO_0000274), Psoriatic Arthritis (EFO_0003778), Hidradenitis Suppurativa (EFO_1000710), Systemic Lupus Erythematosus (MONDO_0007915), Rheumatoid Arthritis (EFO_0000685), Ulcerative Colitis (EFO_0000729), Immune System Disease (EFO_0000540)", 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'JAK3 (ENSG00000105639), JAK1 (ENSG00000162434), JAK2 (ENSG00000096968), TYK2 (ENSG00000105397)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1946 | Q17 | What gene does the drug Decamethonium target? | The drug Decamethonium targets 5 genes: CHRNB1, CHRNA1, CHRND, CHRNE and CHRNG. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%decamethonium%" OR LOWER(tradeNames_string) LIKE "%decamethonium%" OR LOWER(drugSynonyms_string) LIKE "%decamethonium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_922', 'drugName': 'Decamethonium', 'tradeNames_string': '', 'drugSynonyms_string': 'Decamethonium, Decamethonium cation, Decamethonium ion, Syncurine', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_5170', 'drugName': 'Decamethonium Bromide', 'tradeNames_string': 'Syncurine', 'drugSynonyms_string': 'Decamethonium Bromide, Decamethonium bromide, Decamethonium diiodide, Decamethonium iodide, NSC-23004', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'numberLinkedTargets': 5}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1581 | Q17 | What gene does the drug Propiomazine Hydrochloride target? | The drug Propiomazine Hydrochloride targets the gene HRH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%propiomazine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%propiomazine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%propiomazine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3422', 'drugName': 'Propiomazine Hydrochloride', 'tradeNames_string': 'Largon', 'drugSynonyms_string': 'Propiomazine hcl, Propiomazine hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1960, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1490 | Q17 | What gene does the drug Levallorphan target? | The drug Levallorphan targets 2 genes: OPRK1 and OPRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%levallorphan%" OR LOWER(tradeNames_string) LIKE "%levallorphan%" OR LOWER(drugSynonyms_string) LIKE "%levallorphan%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2630', 'drugName': 'Levallorphan', 'tradeNames_string': '', 'drugSynonyms_string': 'Levallorphan, Lorfan, Naloxiphan', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2629', 'drugName': 'Levallorphan', 'tradeNames_string': '', 'drugSynonyms_string': 'Levallorphan, Lorfan, Naloxiphan', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5566', 'drugName': 'Levallorphan Tartrate', 'tradeNames_string': 'Lorfan', 'drugSynonyms_string': 'Levallorphan tartrate, Naloxiphane tartrate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038), OPRK1 (ENSG00000082556)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5565', 'drugName': 'Levallorphan Tartrate', 'tradeNames_string': 'Lorfan', 'drugSynonyms_string': 'Levallorphan tartrate, Naloxiphane tartrate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038), OPRK1 (ENSG00000082556)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.410 | Q17 | What gene does the drug Epoetin Theta target? | The drug Epoetin Theta targets the gene EPOR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%epoetin theta%" OR LOWER(tradeNames_string) LIKE "%epoetin theta%" OR LOWER(drugSynonyms_string) LIKE "%epoetin theta%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6035', 'drugName': 'Epoetin Theta', 'tradeNames_string': 'Eporatio', 'drugSynonyms_string': 'Epoetin theta', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EPOR (ENSG00000187266)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1728 | Q17 | What gene does the drug Amitriptyline Hydrochloride target? | The drug Amitriptyline Hydrochloride targets 2 genes: SLC6A4 and SLC6A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%amitriptyline hydrochloride%" OR LOWER(tradeNames_string) LIKE "%amitriptyline hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%amitriptyline hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3357', 'drugName': 'Amitriptyline Hydrochloride', 'tradeNames_string': 'Amitid, Amitril, Amitriptyline hydrochloride, Cytriptyline, Domical, Elavil, Endep, Lentizol, Limbitrol 5, Saroten, Saroten retard, Triptafen, Triptafen-m, Tryptizol, Tryptizol-75', 'drugSynonyms_string': 'Amitriptyline hcl, Amitriptyline hydrochloride, Amitriptylini hydrochloridum, Etravil, NIH 10794, NSC-104210, Novoprotect, Syneudon', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Pruritus (HP_0000989), Peripheral Nervous System Disease (EFO_0009387)', 'yearOfFirstApproval': 1961, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3358', 'drugName': 'Amitriptyline Hydrochloride', 'tradeNames_string': 'Amitid, Amitril, Amitriptyline hydrochloride, Cytriptyline, Domical, Elavil, Endep, Lentizol, Limbitrol 5, Saroten, Saroten retard, Triptafen, Triptafen-m, Tryptizol, Tryptizol-75', 'drugSynonyms_string': 'Amitriptyline hcl, Amitriptyline hydrochloride, Amitriptylini hydrochloridum, Etravil, NIH 10794, NSC-104210, Novoprotect, Syneudon', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Pruritus (HP_0000989), Peripheral Nervous System Disease (EFO_0009387)', 'yearOfFirstApproval': 1961, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1298 | Q17 | What gene does the drug Pha-793887 target? | The drug Pha-793887 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 20 genes: CDK9, CDK19, CDK3, CDK20, CDK16, CDK18, CDK5, CDK13, CDK12, CDK15, CDK14, CDK10, CDK11B, CDK8, CDK4, CDK2, CDK1, CDK7, CDK17 and CDK6 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pha-793887%" OR LOWER(tradeNames_string) LIKE "%pha-793887%" OR LOWER(drugSynonyms_string) LIKE "%pha-793887%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1722', 'drugName': 'Pha-793887', 'tradeNames_string': '', 'drugSynonyms_string': 'PHA-793887, Pha-793887', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'CDK1 (ENSG00000170312), CDK4 (ENSG00000135446), CDK2 (ENSG00000123374), CDK5 (ENSG00000164885), CDK6 (ENSG00000105810), CDK7 (ENSG00000134058), CDK3 (ENSG00000250506), CDK16 (ENSG00000102225), CDK18 (ENSG00000117266), CDK8 (ENSG00000132964), CDK17 (ENSG00000059758), CDK11B (ENSG00000248333), CDK15 (ENSG00000138395), CDK19 (ENSG00000155111), CDK14 (ENSG00000058091), CDK9 (ENSG00000136807), CDK10 (ENSG00000185324), CDK13 (ENSG00000065883), CDK20 (ENSG00000156345), CDK12 (ENSG00000167258)', 'numberLinkedTargets': 20}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1665 | Q17 | What gene does the drug Brexanolone target? | The drug Brexanolone targets 16 genes: GABRG2, GABRE, GABRA4, GABRQ, GABRD, GABRA3, GABRP, GABRA5, GABRG3, GABRB2, GABRB3, GABRG1, GABRA2, GABRB1, GABRA6 and GABRA1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%brexanolone%" OR LOWER(tradeNames_string) LIKE "%brexanolone%" OR LOWER(drugSynonyms_string) LIKE "%brexanolone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2024', 'drugName': 'Brexanolone', 'tradeNames_string': 'Zulresso', 'drugSynonyms_string': 'Allopregnan-3.alpha.-ol-20-one, Allopregnanolone, Allotetrahydroprogesterone, Brexanolone, SAGE-547, SGE-102', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Post-Traumatic Stress Disorder (EFO_0001358), Alzheimer Disease (MONDO_0004975), Postpartum Depression (EFO_0007453), Essential Tremor (EFO_0003108), Brain Injury (MONDO_0043510), Depressive Disorder (MONDO_0002050), Status Epilepticus (EFO_0008526), Alcohol Dependence (MONDO_0007079)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.107 | Q17 | What gene does the drug Pralidoxime target? | The drug Pralidoxime targets the gene ACHE. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pralidoxime%" OR LOWER(tradeNames_string) LIKE "%pralidoxime%" OR LOWER(drugSynonyms_string) LIKE "%pralidoxime%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5352', 'drugName': 'Pralidoxime', 'tradeNames_string': '', 'drugSynonyms_string': 'Atnaa, Duodote, Pralidoxime, Pralidoxime cation, Pralidoxime ion', 'linkedDiseasesDrug_string': 'Myasthenia Gravis (EFO_0004991), Poisoning (EFO_0008546), Organophosphate Poisoning (EFO_0010581)', 'yearOfFirstApproval': 1964, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACHE (ENSG00000087085)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4265', 'drugName': 'Pralidoxime Chloride', 'tradeNames_string': '2-Pam, Contrathion, Duodote, Pralidoxime chloride, Pralidoxime chloride (autoinjector), Protopam, Protopam chloride', 'drugSynonyms_string': '2-PAM, 2-PAM CHLORIDE, 2-PAM Chloride, NSC-164614, Pralidoxime chloride, Protopam', 'linkedDiseasesDrug_string': 'Myasthenia Gravis (EFO_0004991), Poisoning (EFO_0008546)', 'yearOfFirstApproval': 1964, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACHE (ENSG00000087085)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.695 | Q17 | What gene does the drug Acamprosate target? | The drug Acamprosate targets 23 genes: GRIN3B, GABRG2, GABRA4, GRIN3A, GABRB3, GABRA2, GABRA1, GRIN2B, GRIN2A, GABRE, GABRP, GABRG3, GABRB1, GRIN1, GABRA6, GABRA5, GABRQ, GABRD, GABRA3, GABRB2, GRIN2D, GABRG1 and GRIN2C. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%acamprosate%" OR LOWER(tradeNames_string) LIKE "%acamprosate%" OR LOWER(drugSynonyms_string) LIKE "%acamprosate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_163', 'drugName': 'Acamprosate Calcium', 'tradeNames_string': 'Acamprosate calcium, Campral, Campral ec', 'drugSynonyms_string': 'Acamprosate calcium, NSC-759186, SN-102', 'linkedDiseasesDrug_string': 'Alcohol Dependence (MONDO_0007079)', 'yearOfFirstApproval': 2004, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'numberLinkedTargets': 23}, {'UUID': 'DrugGeneTargets_v2_164', 'drugName': 'Acamprosate Calcium', 'tradeNames_string': 'Acamprosate calcium, Campral, Campral ec', 'drugSynonyms_string': 'Acamprosate calcium, NSC-759186, SN-102', 'linkedDiseasesDrug_string': 'Alcohol Dependence (MONDO_0007079)', 'yearOfFirstApproval': 2004, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'numberLinkedTargets': 23}, {'UUID': 'DrugGeneTargets_v2_1046', 'drugName': 'Acamprosate', 'tradeNames_string': '', 'drugSynonyms_string': 'Acamprosate', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Methamphetamine Dependence (EFO_0004701), Fragile X Syndrome (MONDO_0010383), Dementia (HP_0000726), Anxiety (EFO_0005230), Tinnitus (HP_0000360), Cocaine Dependence (EFO_0002610), Depressive Disorder (MONDO_0002050), Eating Disorder (EFO_0005203), Autism Spectrum Disorder (EFO_0003756), Schizophrenia (MONDO_0005090), Alcohol Dependence (MONDO_0007079)', 'yearOfFirstApproval': 2004, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 23}, {'UUID': 'DrugGeneTargets_v2_1047', 'drugName': 'Acamprosate', 'tradeNames_string': '', 'drugSynonyms_string': 'Acamprosate', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Methamphetamine Dependence (EFO_0004701), Fragile X Syndrome (MONDO_0010383), Dementia (HP_0000726), Anxiety (EFO_0005230), Tinnitus (HP_0000360), Cocaine Dependence (EFO_0002610), Depressive Disorder (MONDO_0002050), Eating Disorder (EFO_0005203), Autism Spectrum Disorder (EFO_0003756), Schizophrenia (MONDO_0005090), Alcohol Dependence (MONDO_0007079)', 'yearOfFirstApproval': 2004, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 23}, {'UUID': 'DrugGeneTargets_v2_3123', 'drugName': 'Tramiprosate', 'tradeNames_string': '', 'drugSynonyms_string': '3-aminopropane sulfonic acid, Acamprosate related compound a, Homotaurine, NC-758, NSC-77071, Tramiprosate', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'APP (ENSG00000142192)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1305 | Q17 | What gene does the drug Trametinib Dimethyl Sulfoxide target? | The drug Trametinib Dimethyl Sulfoxide targets 2 genes: MAP2K2 and MAP2K1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%trametinib dimethyl sulfoxide%" OR LOWER(tradeNames_string) LIKE "%trametinib dimethyl sulfoxide%" OR LOWER(drugSynonyms_string) LIKE "%trametinib dimethyl sulfoxide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3248', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_string': 'Mekinist', 'drugSynonyms_string': 'GSK-1120212B, GSK1120212B, Trametinib dimethyl sulfoxide', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Erdheim-Chester Disease (EFO_1000926), Multiple Myeloma (EFO_0001378), Lung Cancer (MONDO_0008903), Thyroid Cancer (MONDO_0002108), Metastatic Melanoma (EFO_0002617), Cutaneous Melanoma (EFO_0000389)', 'yearOfFirstApproval': 2013, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MAP2K2 (ENSG00000126934), MAP2K1 (ENSG00000169032)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3249', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_string': 'Mekinist', 'drugSynonyms_string': 'GSK-1120212B, GSK1120212B, Trametinib dimethyl sulfoxide', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Erdheim-Chester Disease (EFO_1000926), Multiple Myeloma (EFO_0001378), Lung Cancer (MONDO_0008903), Thyroid Cancer (MONDO_0002108), Metastatic Melanoma (EFO_0002617), Cutaneous Melanoma (EFO_0000389)', 'yearOfFirstApproval': 2013, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MAP2K2 (ENSG00000126934), MAP2K1 (ENSG00000169032)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.833 | Q17 | What gene does the drug Pantoprazole Sodium target? | The drug Pantoprazole Sodium targets 2 genes: ATP4B and ATP4A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pantoprazole sodium%" OR LOWER(tradeNames_string) LIKE "%pantoprazole sodium%" OR LOWER(drugSynonyms_string) LIKE "%pantoprazole sodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1903', 'drugName': 'Pantoprazole Sodium', 'tradeNames_string': 'Pantoprazole sodium, Protonix, Protonix iv', 'drugSynonyms_string': 'Controloc control, Pantoprazole (as sodium), Pantoprazole sodium, Pantoprazole sodium hydrate, Pantoprazole sodium sesquihydrate, Pantozol control, Somac control', 'linkedDiseasesDrug_string': 'Esophagitis (HP_0100633), Neoplasm (EFO_0000616), Fish-Eye Disease (Orphanet_79292), Zollinger-Ellison Syndrome (EFO_0007549), Gastroesophageal Reflux Disease (EFO_0003948)', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ATP4A (ENSG00000105675), ATP4B (ENSG00000186009)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.64 | Q17 | What gene does the drug Anileridine target? | The drug Anileridine targets 2 genes: OPRK1 and OPRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%anileridine%" OR LOWER(tradeNames_string) LIKE "%anileridine%" OR LOWER(drugSynonyms_string) LIKE "%anileridine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4939', 'drugName': 'Anileridine Phosphate', 'tradeNames_string': 'Leritine', 'drugSynonyms_string': 'Anileridine phosphate, Leritine phosphate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038), OPRK1 (ENSG00000082556)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1554', 'drugName': 'Anileridine', 'tradeNames_string': '', 'drugSynonyms_string': 'Adopol, Alidine, Anileridine, Apidol, IDS-NA-012, Leritin, Nipecotan', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038), OPRK1 (ENSG00000082556)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1553', 'drugName': 'Anileridine', 'tradeNames_string': '', 'drugSynonyms_string': 'Adopol, Alidine, Anileridine, Apidol, IDS-NA-012, Leritin, Nipecotan', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038), OPRK1 (ENSG00000082556)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4595', 'drugName': 'Anileridine Hydrochloride', 'tradeNames_string': 'Leritine', 'drugSynonyms_string': 'Aldine, Anileridine dihydrochloride, Anileridine hcl, Anileridine hydrochloride, Anileridine hydrochloride cii, Apodol, Leritine dihydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038), OPRK1 (ENSG00000082556)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4938', 'drugName': 'Anileridine Phosphate', 'tradeNames_string': 'Leritine', 'drugSynonyms_string': 'Anileridine phosphate, Leritine phosphate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038), OPRK1 (ENSG00000082556)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4594', 'drugName': 'Anileridine Hydrochloride', 'tradeNames_string': 'Leritine', 'drugSynonyms_string': 'Aldine, Anileridine dihydrochloride, Anileridine hcl, Anileridine hydrochloride, Anileridine hydrochloride cii, Apodol, Leritine dihydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038), OPRK1 (ENSG00000082556)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.859 | Q17 | What gene does the drug Fulvestrant target? | The drug Fulvestrant targets 2 genes: ESR2 and ESR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fulvestrant%" OR LOWER(tradeNames_string) LIKE "%fulvestrant%" OR LOWER(drugSynonyms_string) LIKE "%fulvestrant%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5561', 'drugName': 'Fulvestrant', 'tradeNames_string': 'Faslodex', 'drugSynonyms_string': 'Faslodex, Fulvestrant, ICI 182,780, ICI-182780, NSC-759879, ZD-9238, ZD9238', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Genital Neoplasm, Female (EFO_1001331), Non-Hodgkins Lymphoma (EFO_0005952), Pulmonary Arterial Hypertension (EFO_0001361), Urothelial Carcinoma (EFO_0008528), Breast Ductal Adenocarcinoma (EFO_0006318), Systemic Lupus Erythematosus (MONDO_0007915), Endometrial Stromal Sarcoma (EFO_1000919), Mccune-Albright Syndrome (MONDO_0018919), Colorectal Carcinoma (EFO_1001951), Endometrial Cancer (MONDO_0011962), Ovarian Cancer (MONDO_0008170), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Breast Neoplasm (EFO_0003869), Prostate Cancer (MONDO_0008315), Uterine Neoplasm (EFO_0003859), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Metastasis (EFO_0009708), Endometrial Carcinoma (EFO_1001512), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Carcinoma (EFO_0000313), Breast Ductal Carcinoma In Situ (EFO_0000432), Precocious Puberty (MONDO_0000088), Invasive Lobular Carcinoma (EFO_0000553), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Hereditary Breast And Ovarian Cancer Syndrome (Orphanet_145)', 'yearOfFirstApproval': 2002, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ESR2 (ENSG00000140009), ESR1 (ENSG00000091831)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1355 | Q17 | What gene does the drug Quazepam target? | The drug Quazepam targets 16 genes: GABRG2, GABRE, GABRA4, GABRQ, GABRD, GABRA3, GABRP, GABRA5, GABRG3, GABRB2, GABRB3, GABRG1, GABRA2, GABRB1, GABRA6 and GABRA1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%quazepam%" OR LOWER(tradeNames_string) LIKE "%quazepam%" OR LOWER(drugSynonyms_string) LIKE "%quazepam%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3979', 'drugName': 'Quazepam', 'tradeNames_string': 'Doral', 'drugSynonyms_string': 'NSC-309702, Quazepam, Quazepam civ, SCH 16134, SCH-16134', 'linkedDiseasesDrug_string': 'Insomnia (EFO_0004698)', 'yearOfFirstApproval': 1985, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.226 | Q17 | What gene does the drug Cenisertib target? | The drug Cenisertib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 3 genes: AURKB, AURKC and AURKA | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cenisertib%" OR LOWER(tradeNames_string) LIKE "%cenisertib%" OR LOWER(drugSynonyms_string) LIKE "%cenisertib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1559', 'drugName': 'Cenisertib', 'tradeNames_string': '', 'drugSynonyms_string': 'AS 703569, AS-703569, AS703569, As-703569, As703569, Aurora kinase inhibitor as703569, Cenisertib, R 763, R-763', 'linkedDiseasesDrug_string': 'Lymphoid Neoplasm (EFO_0001642), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'AURKB (ENSG00000178999), AURKC (ENSG00000105146), AURKA (ENSG00000087586)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.148 | Q17 | What gene does the drug Pralatrexate target? | The drug Pralatrexate targets the gene DHFR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pralatrexate%" OR LOWER(tradeNames_string) LIKE "%pralatrexate%" OR LOWER(drugSynonyms_string) LIKE "%pralatrexate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_39', 'drugName': 'Pralatrexate', 'tradeNames_string': 'Folotyn', 'drugSynonyms_string': 'NSC-754230, PDX, Pralatrexate', 'linkedDiseasesDrug_string': "Sezary'S Disease (EFO_1000785), Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Anaplastic Large Cell Lymphoma (EFO_0003032), Ovarian Cancer (MONDO_0008170), Breast Carcinoma (EFO_0000305), Lymphoma (EFO_0000574), Mycosis Fungoides (EFO_1001051), Peritoneum Cancer (MONDO_0002087), Cutaneous T-Cell Lymphoma (EFO_0002913), Mature T-Cell And Nk-Cell Non-Hodgkin Lymphoma (MONDO_0000430), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), T-Cell Non-Hodgkin Lymphoma (MONDO_0015760), Non-Small Cell Lung Carcinoma (EFO_0003060), Adult T-Cell Leukemia/Lymphoma (MONDO_0019471), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211)", 'yearOfFirstApproval': 2009, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DHFR (ENSG00000228716)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1097 | Q17 | What gene does the drug Thiethylperazine Maleate target? | The drug Thiethylperazine Maleate targets the gene DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%thiethylperazine maleate%" OR LOWER(tradeNames_string) LIKE "%thiethylperazine maleate%" OR LOWER(drugSynonyms_string) LIKE "%thiethylperazine maleate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_101', 'drugName': 'Thiethylperazine Maleate', 'tradeNames_string': 'Torecan', 'drugSynonyms_string': 'GS-95, NSC-130044, Thiethylperazine dimaleate, Thiethylperazine maleate, Thietylperazine maleate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1961, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.379 | Q17 | What gene does the drug Pf-03446879 target? | The drug Pf-03446879 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene MSTN. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pf-03446879%" OR LOWER(tradeNames_string) LIKE "%pf-03446879%" OR LOWER(drugSynonyms_string) LIKE "%pf-03446879%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1591', 'drugName': 'Pf-03446879', 'tradeNames_string': '', 'drugSynonyms_string': 'PF-03446879', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': -1, 'drugIsApproved': False, 'newLinkedTargets_string': 'MSTN (ENSG00000138379)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1422 | Q17 | What gene does the drug Belinostat target? | The drug Belinostat targets 11 genes: HDAC4, HDAC3, HDAC2, HDAC1, HDAC5, HDAC7, HDAC8, HDAC9, HDAC11, HDAC6 and HDAC10. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%belinostat%" OR LOWER(tradeNames_string) LIKE "%belinostat%" OR LOWER(drugSynonyms_string) LIKE "%belinostat%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1601', 'drugName': 'Belinostat', 'tradeNames_string': 'Beleodaq', 'drugSynonyms_string': 'Belinostat, NSC-726630, NSC726630, PX-105684, PXD-101, PXD101', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Non-Hodgkins Lymphoma (EFO_0005952), Thymic Carcinoma (EFO_1000576), Anaplastic Large Cell Lymphoma (EFO_0003032), Urothelial Carcinoma (EFO_0008528), Burkitts Lymphoma (EFO_0000309), Myelodysplastic Syndrome (EFO_0000198), Blast Phase Chronic Myelogenous Leukemia, Bcr-Abl1 Positive (EFO_1000131), Lymphoid Neoplasm (EFO_0001642), Hepatocellular Carcinoma (EFO_0000182), Mantle Cell Lymphoma (EFO_1001469), Lymphoma (EFO_0000574), Acute Myeloid Leukemia (EFO_0000222), Mycosis Fungoides (EFO_1001051), Diffuse Large B-Cell Lymphoma (EFO_0000403), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Soft Tissue Sarcoma (EFO_1001968), Peritoneum Cancer (MONDO_0002087), Carcinoma (EFO_0000313), Cutaneous T-Cell Lymphoma (EFO_0002913), Endometrioid Carcinoma (EFO_0000466), Hodgkins Lymphoma (EFO_0000183), Thymoma (EFO_1000581), Mature T-Cell And Nk-Cell Non-Hodgkin Lymphoma (MONDO_0000430), Follicular Lymphoma (MONDO_0018906), Fallopian Tube Cancer (MONDO_0002158), Neoplasm (EFO_0000616), Ovarian Serous Cystadenocarcinoma (EFO_1000043), Adenocarcinoma (EFO_0000228), T-Cell Non-Hodgkin Lymphoma (MONDO_0015760), Non-Small Cell Lung Carcinoma (EFO_0003060), Glioblastoma Multiforme (EFO_0000519), Adult T-Cell Leukemia/Lymphoma (MONDO_0019471), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211)', 'yearOfFirstApproval': 2014, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HDAC1 (ENSG00000116478), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631), HDAC2 (ENSG00000196591), HDAC5 (ENSG00000108840), HDAC7 (ENSG00000061273), HDAC8 (ENSG00000147099), HDAC11 (ENSG00000163517), HDAC4 (ENSG00000068024), HDAC9 (ENSG00000048052), HDAC10 (ENSG00000100429)', 'numberLinkedTargets': 11}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1152 | Q17 | What gene does the drug Flumazenil target? | The drug Flumazenil targets 16 genes: GABRG2, GABRE, GABRA4, GABRQ, GABRD, GABRA3, GABRP, GABRA5, GABRG3, GABRB2, GABRB3, GABRG1, GABRA2, GABRB1, GABRA6 and GABRA1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%flumazenil%" OR LOWER(tradeNames_string) LIKE "%flumazenil%" OR LOWER(drugSynonyms_string) LIKE "%flumazenil%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4253', 'drugName': 'Flumazenil', 'tradeNames_string': 'Anexate, Flumazenil, Flumazepil, Mazicon, Romazicon', 'drugSynonyms_string': 'Flumazenil, Flumazepil, Lanexat, Mazicon, NSC-759193, RO 15-1788/000, RO-15-1788, RO-151788, RO-151788000, RO-1722, RO-41-8157', 'linkedDiseasesDrug_string': 'Idiopathic Hypersomnia (MONDO_0018044), Drug Dependence (EFO_0003890), Obsessive-Compulsive Disorder (EFO_0004242), Fragile X Syndrome (MONDO_0010383), Parkinson Disease (MONDO_0005180), Narcolepsy (MONDO_0021107), Anxiety (EFO_0005230), Insomnia (EFO_0004698), Alcohol Dependence (MONDO_0007079)', 'yearOfFirstApproval': 1991, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1828 | Q17 | What gene does the drug Plx-8394 target? | The drug Plx-8394 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene BRAF. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%plx-8394%" OR LOWER(tradeNames_string) LIKE "%plx-8394%" OR LOWER(drugSynonyms_string) LIKE "%plx-8394%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2232', 'drugName': 'Plx-8394', 'tradeNames_string': '', 'drugSynonyms_string': 'FORE-8394, FORE8394, PLX8394, Plx 8394, Plx-8394', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Melanoma (EFO_0000756), Thyroid Cancer (MONDO_0002108), Histiocytosis (HP_0100727), Colorectal Carcinoma (EFO_1001951), Cholangiocarcinoma (EFO_0005221), Hairy Cell Leukemia (EFO_1000956)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'BRAF (ENSG00000157764)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1496 | Q17 | What gene does the drug Dabrafenib target? | The drug Dabrafenib targets the gene BRAF. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dabrafenib%" OR LOWER(tradeNames_string) LIKE "%dabrafenib%" OR LOWER(drugSynonyms_string) LIKE "%dabrafenib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_441', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_string': 'Tafinlar', 'drugSynonyms_string': 'Dabrafenib mesilate, Dabrafenib mesylate, GSK-2118436 METHANESULFONATE SALT, GSK-2118436B, GSK-2118436B MESYLATE, GSK-2118436B METHANESULFONATE SALT, GSK2118436B, GSK2118436B, METHANE SULFONATE SALT, METHANE SULFONATE SALT', 'linkedDiseasesDrug_string': 'Erdheim-Chester Disease (EFO_1000926), Multiple Myeloma (EFO_0001378), Thyroid Carcinoma (EFO_0002892), Melanoma (EFO_0000756), Thyroid Cancer (MONDO_0002108), Metastatic Melanoma (EFO_0002617), Cutaneous Melanoma (EFO_0000389)', 'yearOfFirstApproval': 2013, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'BRAF (ENSG00000157764)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5089', 'drugName': 'Dabrafenib', 'tradeNames_string': 'Tafinlar', 'drugSynonyms_string': 'Dabrafenib, GSK-2118436, GSK-2118436A, GSK2118436A, Gsk2118436', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Thyroid Carcinoma (EFO_0002892), Liver Disease (EFO_0001421), Metastatic Melanoma (EFO_0002617), Ameloblastoma (MONDO_0017795), Malignant Glioma (MONDO_0100342), Erdheim-Chester Disease (EFO_1000926), Undifferentiated Carcinoma (EFO_0006772), Thyroid Cancer (MONDO_0002108), Brain Neoplasm (EFO_0003833), Cutaneous Melanoma (EFO_0000389), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Melanoma (EFO_0000756), Kidney Disease (EFO_0003086), Follicular Thyroid Carcinoma (EFO_0000501)', 'yearOfFirstApproval': 2013, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'BRAF (ENSG00000157764)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1602 | Q17 | What gene does the drug Chlorpropamide target? | The drug Chlorpropamide targets 2 genes: KCNJ11 and ABCC8. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%chlorpropamide%" OR LOWER(tradeNames_string) LIKE "%chlorpropamide%" OR LOWER(drugSynonyms_string) LIKE "%chlorpropamide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_951', 'drugName': 'Chlorpropamide', 'tradeNames_string': 'Chlorpropamide, Diabemide, Diabinese, Glucamide, Glymese, Melitase', 'drugSynonyms_string': 'Chlorpropamide, NSC-44634, NSC-626720', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Type 2 Diabetes Mellitus (MONDO_0005148)', 'yearOfFirstApproval': 1958, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNJ11 (ENSG00000187486), ABCC8 (ENSG00000006071)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1759 | Q17 | What gene does the drug Ispronicline target? | The drug Ispronicline is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: CHRNA4 and CHRNB2 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ispronicline%" OR LOWER(tradeNames_string) LIKE "%ispronicline%" OR LOWER(drugSynonyms_string) LIKE "%ispronicline%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6148', 'drugName': 'Ispronicline', 'tradeNames_string': '', 'drugSynonyms_string': 'AZD-3480, Azd3480, Ispronicline, TC-01734, TC-1734', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888), Schizophrenia (MONDO_0005090), Memory Impairment (EFO_0001072), Alzheimer Disease (MONDO_0004975)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CHRNB2 (ENSG00000160716), CHRNA4 (ENSG00000101204)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.10 | Q17 | What gene does the drug Domperidone target? | The drug Domperidone targets the gene DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%domperidone%" OR LOWER(tradeNames_string) LIKE "%domperidone%" OR LOWER(drugSynonyms_string) LIKE "%domperidone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4058', 'drugName': 'Domperidone', 'tradeNames_string': 'Domilium, Evoxin, Motilium, Motilium 10, Motilium instants, Vivadone', 'drugSynonyms_string': 'Domperidone, NSC-299589, NSC-759575, R 33,812, R-33812', 'linkedDiseasesDrug_string': 'Premature Birth (EFO_0003917), Chronic Progressive Multiple Sclerosis (EFO_0003840), Parkinson Disease (MONDO_0005180), Dyspepsia (EFO_0008533), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Gastroparesis (EFO_1000948), Gastroesophageal Reflux Disease (EFO_0003948), Gastrointestinal Disease (EFO_0010282), Gastroenteritis (EFO_1001463)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.455 | Q17 | What gene does the drug Bay-1125976 target? | The drug Bay-1125976 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: AKT2 and AKT1 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bay-1125976%" OR LOWER(tradeNames_string) LIKE "%bay-1125976%" OR LOWER(drugSynonyms_string) LIKE "%bay-1125976%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_481', 'drugName': 'Bay-1125976', 'tradeNames_string': '', 'drugSynonyms_string': 'BAY-1125976, BAY1125976, Bay 1125976, Bay-1125976', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'AKT1 (ENSG00000142208), AKT2 (ENSG00000105221)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_482', 'drugName': 'Bay-1125976', 'tradeNames_string': '', 'drugSynonyms_string': 'BAY-1125976, BAY1125976, Bay 1125976, Bay-1125976', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'AKT1 (ENSG00000142208), AKT2 (ENSG00000105221)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.715 | Q17 | What gene does the drug Ketotifen target? | The drug Ketotifen targets the gene HRH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ketotifen%" OR LOWER(tradeNames_string) LIKE "%ketotifen%" OR LOWER(drugSynonyms_string) LIKE "%ketotifen%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5638', 'drugName': 'Ketotifen Fumarate', 'tradeNames_string': "Acuvue theravision with ketotifen, Alaway, Children's alaway, Ketotifen fumarate, Zaditen, Zaditor", 'drugSynonyms_string': 'HC 20,511 FUMARATE, HC-20511 FUMARATE, Ketotifen (as fumarate), Ketotifen fumarate, Ketotifen hydrogen fumarate, NSC-757415', 'linkedDiseasesDrug_string': 'Allergic Conjunctivitis (EFO_0007141), Rhinitis, Allergic, Perennial (EFO_1001417), Chronic Pain (HP_0012532), Atopic Eczema (EFO_0000274), Bone Fracture (EFO_0003931), Dermatitis (MONDO_0002406)', 'yearOfFirstApproval': 1999, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5435', 'drugName': 'Ketotifen', 'tradeNames_string': '', 'drugSynonyms_string': '(R)-Ketotifen, Ketotifen', 'linkedDiseasesDrug_string': 'Allergic Conjunctivitis (EFO_0007141), Flexion Contracture (HP_0001371), Bone Fracture (EFO_0003931), Rhinitis, Allergic, Perennial (EFO_1001417), Chronic Pain (HP_0012532), Atopic Eczema (EFO_0000274), Covid-19 (MONDO_0100096), Dyspepsia (EFO_0008533), Fibromyalgia (EFO_0005687), Eye Allergy (EFO_0005751), Allergic Disease (MONDO_0005271), Peanut Allergic Reaction (EFO_0007425), Dermatitis (MONDO_0002406)', 'yearOfFirstApproval': 1999, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.258 | Q17 | What gene does the drug Ruxolitinib target? | The drug Ruxolitinib targets 2 genes: JAK1 and JAK2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ruxolitinib%" OR LOWER(tradeNames_string) LIKE "%ruxolitinib%" OR LOWER(drugSynonyms_string) LIKE "%ruxolitinib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1728', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_string': 'Jakafi, Opzelura', 'drugSynonyms_string': 'INCB-018424 PHOSPHATE, INCB-018424 SALT, INCB-18424 PHOSPHATE, INCB018424 PHOSPHATE, INCB018424 SALT, Opzelura, Ruxolitinib (as phosphate), Ruxolitinib monophosphate, Ruxolitinib phosphate', 'linkedDiseasesDrug_string': 'Myelofibrosis (HP_0011974), Psoriasis (EFO_0000676), Primary Myelofibrosis (EFO_0002430), Fallopian Tube Cancer (MONDO_0002158), Chronic Lymphocytic Leukemia (EFO_0000095), Alopecia Areata (EFO_0004192), Atopic Eczema (EFO_0000274), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Polycythemia Vera (EFO_0002429), Endometrioid Carcinoma (EFO_0000466), Malaria (EFO_0001068), Breast Carcinoma (EFO_0000305)', 'yearOfFirstApproval': 2011, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'JAK1 (ENSG00000162434), JAK2 (ENSG00000096968)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1727', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_string': 'Jakafi, Opzelura', 'drugSynonyms_string': 'INCB-018424 PHOSPHATE, INCB-018424 SALT, INCB-18424 PHOSPHATE, INCB018424 PHOSPHATE, INCB018424 SALT, Opzelura, Ruxolitinib (as phosphate), Ruxolitinib monophosphate, Ruxolitinib phosphate', 'linkedDiseasesDrug_string': 'Myelofibrosis (HP_0011974), Psoriasis (EFO_0000676), Primary Myelofibrosis (EFO_0002430), Fallopian Tube Cancer (MONDO_0002158), Chronic Lymphocytic Leukemia (EFO_0000095), Alopecia Areata (EFO_0004192), Atopic Eczema (EFO_0000274), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Polycythemia Vera (EFO_0002429), Endometrioid Carcinoma (EFO_0000466), Malaria (EFO_0001068), Breast Carcinoma (EFO_0000305)', 'yearOfFirstApproval': 2011, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'JAK1 (ENSG00000162434), JAK2 (ENSG00000096968)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3179', 'drugName': 'Ruxolitinib', 'tradeNames_string': 'Jakavi', 'drugSynonyms_string': 'INC-424, INC424, INCB-018424, INCB-18424, INCB018424, Ruxolitinib', 'linkedDiseasesDrug_string': 'Myelofibrosis (HP_0011974), Psoriasis (EFO_0000676), Multiple Myeloma (EFO_0001378), Cancer (MONDO_0004992), Primary Myelofibrosis (EFO_0002430), Chronic Lymphocytic Leukemia (EFO_0000095), Non-Hodgkins Lymphoma (EFO_0005952), Pneumonia (EFO_0003106), Essential Thrombocythemia (EFO_0000479), Macrophage Activation Syndrome (EFO_1001806), Graft Versus Host Disease (MONDO_0013730), Liver Disease (EFO_0001421), Covid-19 (MONDO_0100096), Hemophagocytic Syndrome (MONDO_0015540), Colorectal Carcinoma (EFO_1001951), Polycythemia Vera (EFO_0002429), Chronic Myelogenous Leukemia (EFO_0000339), Malaria (EFO_0001068), Necrobiosis Lipoidica (EFO_1000738), Breast Carcinoma (EFO_0000305), Bronchiolitis Obliterans (EFO_0007183), Lymphoid Neoplasm (EFO_0001642), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Atopic Eczema (EFO_0000274), Myelofibrosis (MONDO_0044903), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoma (EFO_0000574), Chronic Myelomonocytic Leukemia (EFO_1001779), Acute Myeloid Leukemia (EFO_0000222), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Hypereosinophilic Syndrome (EFO_1001467), Acute Graft Vs. Host Disease (EFO_0004599), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Inflammatory Breast Carcinoma (EFO_1000984), Pancreatic Carcinoma (EFO_0002618), Vitiligo (EFO_0004208), Cachexia (HP_0004326), Alopecia Areata (EFO_0004192), Lichen Planus (EFO_1000726), Rheumatoid Arthritis (EFO_0000685), Endometrioid Carcinoma (EFO_0000466), Hodgkins Lymphoma (EFO_0000183), Eczema (HP_0000964), Discoid Lupus Erythematosus (MONDO_0019558), T-Cell Acute Lymphoblastic Leukemia (EFO_0000209), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Myeloproliferative Disorder (EFO_0004251), Hiv Infection (EFO_0000764), Non-Small Cell Lung Carcinoma (EFO_0003060), Classic Hodgkin Lymphoma (MONDO_0009348), Kidney Disease (EFO_0003086), Beta-Thalassemia Major (MONDO_0016486), Glioblastoma Multiforme (EFO_0000519), Hidradenitis Suppurativa (EFO_1000710), Severe Acute Respiratory Syndrome (EFO_0000694), Dermatitis (MONDO_0002406)', 'yearOfFirstApproval': 2011, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'JAK1 (ENSG00000162434), JAK2 (ENSG00000096968)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3178', 'drugName': 'Ruxolitinib', 'tradeNames_string': 'Jakavi', 'drugSynonyms_string': 'INC-424, INC424, INCB-018424, INCB-18424, INCB018424, Ruxolitinib', 'linkedDiseasesDrug_string': 'Myelofibrosis (HP_0011974), Psoriasis (EFO_0000676), Multiple Myeloma (EFO_0001378), Cancer (MONDO_0004992), Primary Myelofibrosis (EFO_0002430), Chronic Lymphocytic Leukemia (EFO_0000095), Non-Hodgkins Lymphoma (EFO_0005952), Pneumonia (EFO_0003106), Essential Thrombocythemia (EFO_0000479), Macrophage Activation Syndrome (EFO_1001806), Graft Versus Host Disease (MONDO_0013730), Liver Disease (EFO_0001421), Covid-19 (MONDO_0100096), Hemophagocytic Syndrome (MONDO_0015540), Colorectal Carcinoma (EFO_1001951), Polycythemia Vera (EFO_0002429), Chronic Myelogenous Leukemia (EFO_0000339), Malaria (EFO_0001068), Necrobiosis Lipoidica (EFO_1000738), Breast Carcinoma (EFO_0000305), Bronchiolitis Obliterans (EFO_0007183), Lymphoid Neoplasm (EFO_0001642), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Atopic Eczema (EFO_0000274), Myelofibrosis (MONDO_0044903), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoma (EFO_0000574), Chronic Myelomonocytic Leukemia (EFO_1001779), Acute Myeloid Leukemia (EFO_0000222), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Hypereosinophilic Syndrome (EFO_1001467), Acute Graft Vs. Host Disease (EFO_0004599), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Inflammatory Breast Carcinoma (EFO_1000984), Pancreatic Carcinoma (EFO_0002618), Vitiligo (EFO_0004208), Cachexia (HP_0004326), Alopecia Areata (EFO_0004192), Lichen Planus (EFO_1000726), Rheumatoid Arthritis (EFO_0000685), Endometrioid Carcinoma (EFO_0000466), Hodgkins Lymphoma (EFO_0000183), Eczema (HP_0000964), Discoid Lupus Erythematosus (MONDO_0019558), T-Cell Acute Lymphoblastic Leukemia (EFO_0000209), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Myeloproliferative Disorder (EFO_0004251), Hiv Infection (EFO_0000764), Non-Small Cell Lung Carcinoma (EFO_0003060), Classic Hodgkin Lymphoma (MONDO_0009348), Kidney Disease (EFO_0003086), Beta-Thalassemia Major (MONDO_0016486), Glioblastoma Multiforme (EFO_0000519), Hidradenitis Suppurativa (EFO_1000710), Severe Acute Respiratory Syndrome (EFO_0000694), Dermatitis (MONDO_0002406)', 'yearOfFirstApproval': 2011, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'JAK1 (ENSG00000162434), JAK2 (ENSG00000096968)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.889 | Q17 | What gene does the drug Catumaxomab target? | The drug Catumaxomab targets 4 genes: CD3E, CD3G, EPCAM and CD3D. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%catumaxomab%" OR LOWER(tradeNames_string) LIKE "%catumaxomab%" OR LOWER(drugSynonyms_string) LIKE "%catumaxomab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2537', 'drugName': 'Catumaxomab', 'tradeNames_string': 'Removab', 'drugSynonyms_string': 'Catumaxomab', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Fallopian Tube Carcinoma (EFO_1000251), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Gastric Adenocarcinoma (EFO_0000503), Peritoneal Neoplasm (EFO_1001100), Stomach Neoplasm (EFO_0003897), Ovarian Cancer (MONDO_0008170), Ascites (HP_0001541), Bladder Tumor (EFO_0000294)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CD3E (ENSG00000198851), CD3G (ENSG00000160654), CD3D (ENSG00000167286), EPCAM (ENSG00000119888)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_2538', 'drugName': 'Catumaxomab', 'tradeNames_string': 'Removab', 'drugSynonyms_string': 'Catumaxomab', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Fallopian Tube Carcinoma (EFO_1000251), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Gastric Adenocarcinoma (EFO_0000503), Peritoneal Neoplasm (EFO_1001100), Stomach Neoplasm (EFO_0003897), Ovarian Cancer (MONDO_0008170), Ascites (HP_0001541), Bladder Tumor (EFO_0000294)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CD3E (ENSG00000198851), CD3G (ENSG00000160654), CD3D (ENSG00000167286), EPCAM (ENSG00000119888)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.395 | Q17 | What gene does the drug Daunorubicin target? | The drug Daunorubicin targets the gene TOP2A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%daunorubicin%" OR LOWER(tradeNames_string) LIKE "%daunorubicin%" OR LOWER(drugSynonyms_string) LIKE "%daunorubicin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1919', 'drugName': 'Daunorubicin Hydrochloride', 'tradeNames_string': 'Cerubidine, Daunorubicin hydrochloride, Daunoxome', 'drugSynonyms_string': 'Daunorubicin (as hydrochloride), Daunorubicin hcl, Daunorubicin hydrochloride, FI 6339 HYDROCHLORIDE, FI 6339 [AS THE BASE], FI-6339, FI-6339 HYDROCHLORIDE, NDC 0082-4155, NDC-0082-4155, NSC-82151, RP 13057 HYDROCHLORIDE, RP 13057 [AS THE BASE), RP-13057, RP-13057 HYDROCHLORIDE', 'linkedDiseasesDrug_string': 'Refractory Anemia (EFO_0003802), Myelodysplastic Syndrome (EFO_0000198), Myeloid Sarcoma (EFO_1001052), Acute Promyelocytic Leukemia (EFO_0000224), Acute Myelomonocytic Leukemia (EFO_0000223), B-Cell Acute Lymphoblastic Leukemia (EFO_0000094), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoma (EFO_0000574), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Acute Myeloblastic Leukemia Without Maturation (EFO_0003027), Acute Myeloid Leukemia (EFO_0000222), Chronic Myelomonocytic Leukemia (EFO_1001779), Acute Basophilic Leukemia (EFO_0003029), Acute Megakaryoblastic Leukaemia (EFO_0003025), Refractory Anemia With Excess Blasts (EFO_0003811), Acute Erythroleukemia (EFO_0000218), T-Lymphoblastic Lymphoma (MONDO_0044917), T-Cell Acute Lymphoblastic Leukemia (EFO_0000209), Leukemia (EFO_0000565), Myeloproliferative Disorder (EFO_0004251), Sarcoma (EFO_0000691), Acute Myeloblastic Leukemia With Maturation (EFO_0003028), Acute Monocytic Leukemia (EFO_0000221)', 'yearOfFirstApproval': 1979, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TOP2A (ENSG00000131747)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_484', 'drugName': 'Doxorubicin', 'tradeNames_string': 'Adriblastina', 'drugSynonyms_string': 'Adriablastin, Adriamycin, Doxil, Doxorubicin, Epirubicin hydrochloride impurity, doxorubicin-, Hydroxydaunorubicin, NSC-123127, NSC-759155, Rubex, Valrubicin impurity, doxorubicin', 'linkedDiseasesDrug_string': "Ovarian Carcinoma (EFO_0001075), Multiple Myeloma (EFO_0001378), Oligodendroglioma (EFO_0000632), Lymphoplasmacytic Lymphoma (MONDO_0000432), Hemophagocytic Syndrome (MONDO_0015540), Acute Myelomonocytic Leukemia (EFO_0000223), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Liposarcoma (EFO_0000569), Acute Leukemia Of Ambiguous Lineage (MONDO_0019460), Malignant Glioma (MONDO_0100342), Inflammatory Breast Carcinoma (EFO_1000984), Retinoblastoma (MONDO_0008380), Neuroendocrine Neoplasm (EFO_1001901), Urinary Bladder Carcinoma (MONDO_0004986), Myelodysplastic/Myeloproliferative Disease (MONDO_0020077), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Castleman Disease (MONDO_0015564), Carcinoma (EFO_0000313), Breast Ductal Carcinoma In Situ (EFO_0000432), Endometrial Neoplasm (EFO_0004230), Liver Cancer (MONDO_0002691), Cervical Cancer (MONDO_0002974), T-Lymphoblastic Lymphoma (MONDO_0044917), Follicular Lymphoma (MONDO_0018906), Osteosarcoma (EFO_0000637), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Ewing Sarcoma (EFO_0000174), T-Cell Non-Hodgkin Lymphoma (MONDO_0015760), Lymphoma, Aids-Related (EFO_1001365), Classic Hodgkin Lymphoma (MONDO_0009348), Leiomyosarcoma (EFO_0000564), Malignant Pleural Mesothelioma (EFO_0000770), Glioblastoma Multiforme (EFO_0000519), Thyroid Gland Undifferentiated (Anaplastic) Carcinoma (EFO_1000595), Adult T-Cell Leukemia/Lymphoma (MONDO_0019471), Hereditary Breast And Ovarian Cancer Syndrome (Orphanet_145), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Autoimmune Thrombocytopenic Purpura (EFO_0007160), Malignant Bone Neoplasm (EFO_1000350), Thymic Carcinoma (EFO_1000576), Anaplastic Large Cell Lymphoma (EFO_0003032), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Breast Carcinoma In Situ (MONDO_0004658), Angiosarcoma (EFO_0003968), Hepatocellular Carcinoma (EFO_0000182), Fallopian Tube Carcinoma (EFO_1000251), Uterine Neoplasm (EFO_0003859), Mantle Cell Lymphoma (EFO_1001469), Gastric Adenocarcinoma (EFO_0000503), Bone Sarcoma (MONDO_0021054), B-Cell Acute Lymphoblastic Leukemia (EFO_0000094), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Dedifferentiated Liposarcoma (EFO_0003085), Metastasis (EFO_0009708), Carcinosarcoma (MONDO_0002928), Small Cell Lung Carcinoma (EFO_0000702), Triple-Negative Breast Cancer (EFO_0005537), Thyroid Cancer (MONDO_0002108), Salivary Gland Cancer (MONDO_0004669), Malignant Peripheral Nerve Sheath Tumor (EFO_0000760), Cutaneous T-Cell Lymphoma (EFO_0002913), Hodgkins Lymphoma (EFO_0000183), Mature T-Cell And Nk-Cell Non-Hodgkin Lymphoma (MONDO_0000430), Salivary Gland Adenoid Cystic Carcinoma (MONDO_0003175), T-Cell Acute Lymphoblastic Leukemia (EFO_0000209), Non-Small Cell Lung Carcinoma (EFO_0003060), Pediatric Fibrosarcoma (MONDO_0002678), Adrenal Gland Pheochromocytoma (EFO_0000239), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211), Neuroblastoma (EFO_0000621), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Urothelial Carcinoma (EFO_0008528), Aids (EFO_0000765), Hepatoblastoma (EFO_1000292), Blast Phase Chronic Myelogenous Leukemia, Bcr-Abl1 Positive (EFO_1000131), Epithelioid Sarcoma (MONDO_0017387), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Breast Neoplasm (EFO_0003869), Mouth Neoplasm (EFO_0003868), Histiocytoma (EFO_0005561), Anaplastic Astrocytoma (EFO_0002499), Breast Cancer (MONDO_0007254), Embryonal Rhabdomyosarcoma (EFO_0000437), Lymphoma (EFO_0000574), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Wilms Tumor (MONDO_0006058), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Rhabdomyosarcoma (EFO_0002918), Abnormality Of Blood And Blood-Forming Tissues (HP_0001871), Neoplasm Of Mature B-Cells (EFO_0000096), Ganglioneuroblastoma (EFO_0000502), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Cutaneous Melanoma (EFO_0000389), Pilocytic Astrocytoma (MONDO_0016691), Thymoma (EFO_1000581), Choroid Plexus Neoplasm (MONDO_0016717), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Nausea And Vomiting (HP_0002017), Heart Failure (EFO_0003144), Sarcoma (EFO_0000691), Primary Systemic Amyloidosis (MONDO_0017816), Synovial Sarcoma (EFO_0001376), Kidney Wilms Tumor (MONDO_0019004), Alveolar Soft Part Sarcoma (EFO_0007143), Peritoneal Neoplasm (EFO_1001100), Adenoid Cystic Carcinoma (EFO_0000231), Metastatic Melanoma (EFO_0002617), Hemangiopericytoma (MONDO_0005094), Burkitts Lymphoma (EFO_0000309), Angioimmunoblastic T-Cell Lymphoma (EFO_0000255), Plasma Cell Leukemia (EFO_0006475), Endometrial Cancer (MONDO_0011962), B-Cell Neoplasm (MONDO_0004095), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Prostate Cancer (MONDO_0008315), Oligoastrocytoma (EFO_0000630), Neutropenia (MONDO_0001475), Male Breast Carcinoma (EFO_0006861), Urethra Cancer (MONDO_0004192), Dermatofibrosarcoma Protuberans (MONDO_0011934), Childhood Kidney Neoplasm (MONDO_0002730), Extranodal Nasal Nk/T Cell Lymphoma (MONDO_0019472), Lymphoblastic Lymphoma (MONDO_0000873), Soft Tissue Sarcoma (EFO_1001968), Alveolar Rhabdomyosarcoma (EFO_0000248), Lung Neoplasm (MONDO_0021117), Renal Cell Carcinoma (EFO_0000681), Carcinoma Of Liver And Intrahepatic Biliary Tract (MONDO_0018531), Ovarian Neoplasm (EFO_0003893), Lymphoid Leukemia (EFO_0004289), Brain Cancer (MONDO_0001657), Optic Nerve Glioblastoma (EFO_0009254), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Mesenchymoma (EFO_1001042), Nasopharyngeal Neoplasm (EFO_0004252), Adrenal Cortex Carcinoma (EFO_1000796), Kidney Cancer (MONDO_0002367), Kaposi'S Sarcoma (EFO_0000558), Esophageal Cancer (MONDO_0007576)", 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TOP2A (ENSG00000131747)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1471', 'drugName': 'Daunorubicin Citrate', 'tradeNames_string': 'Daunoxome', 'drugSynonyms_string': 'Daunorubicin citrate, Daunorubicin citrate liposome, Daunorubicin liposomal', 'linkedDiseasesDrug_string': 'Leukemia (EFO_0000565), Breast Cancer (MONDO_0007254), Sarcoma (EFO_0000691)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TOP2A (ENSG00000131747)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_881', 'drugName': 'Daunorubicin', 'tradeNames_string': 'Daunoxome', 'drugSynonyms_string': 'Cerubidine, Daunomycin, Daunorubicin, Daunoxome, Epirubicin hydrochloride impurity, daunorubicin-, FI 6339, FI-6339, NSC-83142, RP 13057, RP-13057, Valrubicin impurity, daunorubicin', 'linkedDiseasesDrug_string': "Non-Hodgkins Lymphoma (EFO_0005952), Essential Thrombocythemia (EFO_0000479), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Myeloid Leukemia (MONDO_0004643), Refractory Anemia (EFO_0003802), Myelodysplastic Syndrome (EFO_0000198), Polycythemia Vera (EFO_0002429), Chronic Myelogenous Leukemia (EFO_0000339), Myeloid Sarcoma (EFO_1001052), Acute Promyelocytic Leukemia (EFO_0000224), Breast Cancer (MONDO_0007254), Acute Myelomonocytic Leukemia (EFO_0000223), Chronic Hepatitis B Virus Infection (EFO_0004239), Myelofibrosis (MONDO_0044903), B-Cell Acute Lymphoblastic Leukemia (EFO_0000094), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoma (EFO_0000574), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Acute Myeloblastic Leukemia Without Maturation (EFO_0003027), Acute Myeloid Leukemia (EFO_0000222), Chronic Myelomonocytic Leukemia (EFO_1001779), Acute Basophilic Leukemia (EFO_0003029), Acute Megakaryoblastic Leukaemia (EFO_0003025), Refractory Anemia With Excess Blasts (EFO_0003811), Lymphoblastic Lymphoma (MONDO_0000873), Acute Erythroleukemia (EFO_0000218), T-Lymphoblastic Lymphoma (MONDO_0044917), Lymphoid Leukemia (EFO_0004289), Chronic Kidney Disease (EFO_0003884), T-Cell Acute Lymphoblastic Leukemia (EFO_0000209), Leukemia (EFO_0000565), Myeloproliferative Disorder (EFO_0004251), Neoplasm (EFO_0000616), Kaposi'S Sarcoma (EFO_0000558), Sarcoma (EFO_0000691), Acute Myeloblastic Leukemia With Maturation (EFO_0003028), Acute Monocytic Leukemia (EFO_0000221)", 'yearOfFirstApproval': 1979, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TOP2A (ENSG00000131747)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.916 | Q17 | What gene does the drug Somapacitan target? | The drug Somapacitan targets the gene GHR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%somapacitan%" OR LOWER(tradeNames_string) LIKE "%somapacitan%" OR LOWER(drugSynonyms_string) LIKE "%somapacitan%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3588', 'drugName': 'Somapacitan', 'tradeNames_string': 'Sogroya', 'drugSynonyms_string': 'NN-8640, NN8640, NNC-0195-0092, NNC0195-0092, Somapacitan, Somapacitan beco, Somapacitan-beco', 'linkedDiseasesDrug_string': 'Pituitary Dwarfism (EFO_1001109)', 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GHR (ENSG00000112964)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.932 | Q17 | What gene does the drug Fasiglifam target? | The drug Fasiglifam is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene FFAR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fasiglifam%" OR LOWER(tradeNames_string) LIKE "%fasiglifam%" OR LOWER(drugSynonyms_string) LIKE "%fasiglifam%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1997', 'drugName': 'Fasiglifam', 'tradeNames_string': '', 'drugSynonyms_string': 'Fasiglifam, Fasiglifam hemihydrate, Fasiglifam hydrate, TAK-875, TAK875, Tak-875 anhydrous', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Type 2 Diabetes Mellitus (MONDO_0005148)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'FFAR1 (ENSG00000126266)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1704 | Q17 | What gene does the drug Pramipexole target? | The drug Pramipexole targets 3 genes: DRD3, DRD4 and DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pramipexole%" OR LOWER(tradeNames_string) LIKE "%pramipexole%" OR LOWER(drugSynonyms_string) LIKE "%pramipexole%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_980', 'drugName': 'Pramipexole', 'tradeNames_string': 'Mirapexin, Neliprax, Oprymea, Pipexus', 'drugSynonyms_string': 'NSC-760426, Pramipexole, SUD-919CL2Y, SUD919CL2Y, U-98528E', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975), Substance Abuse (MONDO_0002491), Obsessive-Compulsive Disorder (EFO_0004242), Essential Tremor (EFO_0003108), Amyotrophic Lateral Sclerosis (MONDO_0004976), Chronic Pain (HP_0012532), Renal Colic (EFO_1001412), Schizoaffective Disorder (EFO_0005411), Parkinson Disease (MONDO_0005180), Fibromyalgia (EFO_0005687), Tourette Syndrome (EFO_0004895), Cocaine Dependence (EFO_0002610), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Eating Disorder (EFO_0005203), Schizophrenia (MONDO_0005090), Restless Legs Syndrome (EFO_0004270)', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_5763', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_string': 'Mirapex, Mirapex Extended Release, Mirapex er, Pramipexole dihydrochloride', 'drugSynonyms_string': 'Daquiran, PNU-98528E, Pramipexole accord, Pramipexole dihydrochloride, Pramipexole dihydrochloride anhydrous, Pramipexole dihydrochloride monohydrate, Pramipexole hydrochloride, Pramipexole hydrochloride hydrate, Pramipexole teva, SND-919CL2Y, SND919CL2Y, Sifrol', 'linkedDiseasesDrug_string': 'Restless Legs Syndrome (EFO_0004270), Amyotrophic Lateral Sclerosis (MONDO_0004976), Bipolar Disorder (MONDO_0004985), Parkinson Disease (MONDO_0005180)', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1231 | Q17 | What gene does the drug Itacitinib target? | The drug Itacitinib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene JAK1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%itacitinib%" OR LOWER(tradeNames_string) LIKE "%itacitinib%" OR LOWER(drugSynonyms_string) LIKE "%itacitinib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4250', 'drugName': 'Itacitinib', 'tradeNames_string': '', 'drugSynonyms_string': 'INCB-039110, INCB039110, Incb-039110, Incb-39110, Itacitinib', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676), Cancer (MONDO_0004992), Graft Versus Host Disease (MONDO_0013730), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Hemophagocytic Syndrome (MONDO_0015540), Endometrial Cancer (MONDO_0011962), Ulcerative Colitis (EFO_0000729), Bronchiolitis Obliterans (EFO_0007183), Hepatocellular Carcinoma (EFO_0000182), Breast Cancer (MONDO_0007254), Myelofibrosis (MONDO_0044903), Lymphoma (EFO_0000574), Acute Graft Vs. Host Disease (EFO_0004599), Immune System Disease (EFO_0000540), Pruritus (HP_0000989), Pancreatic Carcinoma (EFO_0002618), Rheumatoid Arthritis (EFO_0000685), Systemic Scleroderma (EFO_0000717), Hodgkins Lymphoma (EFO_0000183), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Myeloproliferative Disorder (EFO_0004251), T-Cell Prolymphocytic Leukemia (EFO_1000560), Classic Hodgkin Lymphoma (MONDO_0009348), Non-Small Cell Lung Carcinoma (EFO_0003060), Melanoma (EFO_0000756), Hematologic Disease (EFO_0005803)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'JAK1 (ENSG00000162434)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.466 | Q17 | What gene does the drug Codeine target? | The drug Codeine targets 3 genes: OPRK1, OPRM1 and OPRD1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%codeine%" OR LOWER(tradeNames_string) LIKE "%codeine%" OR LOWER(drugSynonyms_string) LIKE "%codeine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3666', 'drugName': 'Codeine Sulfate', 'tradeNames_string': 'Codeine sulfate', 'drugSynonyms_string': 'Codeine sulfate, Codeine sulfate anhydrous, Codeine sulfate cii, Codeine sulfate trihydrate, Codeine sulphate', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843)', 'yearOfFirstApproval': 2009, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_4198', 'drugName': 'Dihydrocodeine Bitartrate', 'tradeNames_string': '', 'drugSynonyms_string': 'Codeine, dihydro-, tartrate (1:1), DF 118, DF-118, Dihydrocodeine bitartrate, Dihydrocodeine bitartrate cii, Dihydrocodeine hydrogen tartrate, Dihydrocodeine phosphate, Dihydrocodeine tartrate, Dihydroneopine, Drocode, NSC-117857', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843)', 'yearOfFirstApproval': 1983, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2341', 'drugName': 'Dihydrocodeine', 'tradeNames_string': '', 'drugSynonyms_string': '.alpha.-hydrocodol, 8,14-dihydroneopine, Codhydrine, Dehacodin, Dh-codeine, Dihydrocodeine, IDS-ND-008(SECT.2), NSC-231319, Novicondin, Rapacodin, Remedacen', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843)', 'yearOfFirstApproval': 1983, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4963', 'drugName': 'Codeine', 'tradeNames_string': '', 'drugSynonyms_string': 'Codeine, Codeine monohydrate, Codeinum, Codeinum monohydricum, Dea no. 9050, IDS-NC-005(SECT.-2)', 'linkedDiseasesDrug_string': 'Toothache (EFO_0010072), Head And Neck Malignant Neoplasia (EFO_0006859), Myopia (HP_0000545), Drug Dependence (EFO_0003890), Neck Pain (HP_0030833), Hiv Infection (EFO_0000764), Osteoarthritis (MONDO_0005178), Migraine Disorder (MONDO_0005277), Pain (EFO_0003843), Sickle Cell Anemia (MONDO_0011382), Cough (HP_0012735), Muscle Spasm (HP_0003394), Constipation (HP_0002019), Injury (EFO_0000546)', 'yearOfFirstApproval': 1952, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_494', 'drugName': 'Codeine Polistirex', 'tradeNames_string': '', 'drugSynonyms_string': 'Codeine polistirex', 'linkedDiseasesDrug_string': 'Cough (HP_0012735)', 'yearOfFirstApproval': 1985, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_1990', 'drugName': 'Codeine Phosphate', 'tradeNames_string': 'Ambenyl cough syrup, Bepro, Colrex compound, Evacode, Galcodine', 'drugSynonyms_string': 'Codeine phosphate, Codeine phosphate anhydrous, Codeine phosphate bp, Codeine phosphate cii, Codeine phosphate hemihydrate, Codeine phosphate hydrate, Codeini phosphas, Methylmorphine', 'linkedDiseasesDrug_string': 'Drug Dependence (EFO_0003890), Hiv Infection (EFO_0000764), Migraine Disorder (MONDO_0005277), Cough (HP_0012735), Pain (EFO_0003843), Muscle Spasm (HP_0003394)', 'yearOfFirstApproval': 1952, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1967 | Q17 | What gene does the drug Ritodrine Hydrochloride target? | The drug Ritodrine Hydrochloride targets the gene ADRB2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ritodrine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%ritodrine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%ritodrine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5085', 'drugName': 'Ritodrine Hydrochloride', 'tradeNames_string': 'Ritodrine hydrochloride, Yutopar', 'drugSynonyms_string': 'Luteonin, NSC-291565, Ritodrine hcl, Ritodrine hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1991, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1178 | Q17 | What gene does the drug Arsenic Trioxide target? | The drug Arsenic Trioxide targets the gene TXNRD1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%arsenic trioxide%" OR LOWER(tradeNames_string) LIKE "%arsenic trioxide%" OR LOWER(drugSynonyms_string) LIKE "%arsenic trioxide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_975', 'drugName': 'Arsenic Trioxide', 'tradeNames_string': 'Trisenox', 'drugSynonyms_string': 'Arseneous anhydride, Arseneous oxide, Arsenic oxide, Arsenic oxide (as4o6), Arsenic sesquioxide, Arsenic trioxide, Arsenicum album, Arsenous oxide, Diarsenic trioxide, NSC-759274, NSC-92859, Tetraarsenic hexaoxide, White arsenic', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Neuroblastoma (EFO_0000621), Multiple Myeloma (EFO_0001378), Primary Myelofibrosis (EFO_0002430), Chronic Lymphocytic Leukemia (EFO_0000095), Ureter Cancer (MONDO_0008627), Essential Thrombocythemia (EFO_0000479), Aids (EFO_0000765), Systemic Lupus Erythematosus (MONDO_0007915), Metastatic Melanoma (EFO_0002617), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Polycythemia Vera (EFO_0002429), Chronic Myelogenous Leukemia (EFO_0000339), Acute Promyelocytic Leukemia (EFO_0000224), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Myelofibrosis (MONDO_0044903), Lymphoma (EFO_0000574), Acute Myeloid Leukemia (EFO_0000222), Urethra Cancer (MONDO_0004192), Endometrial Carcinoma (EFO_1001512), Central Nervous System Neoplasm (EFO_1000158), Pancreatic Carcinoma (EFO_0002618), Urinary Bladder Carcinoma (MONDO_0004986), Small Cell Lung Carcinoma (EFO_0000702), Skin Basal Cell Carcinoma (MONDO_0005341), Liver Cancer (MONDO_0002691), Cervical Cancer (MONDO_0002974), Brain Cancer (MONDO_0001657), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Kidney Cancer (MONDO_0002367)', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TXNRD1 (ENSG00000198431)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.967 | Q17 | What gene does the drug Eribulin Mesylate target? | The drug Eribulin Mesylate targets 15 genes: TUBB, TUBA4A, TUBA3E, TUBB3, TUBB4B, TUBB2A, TUBA1A, TUBA1C, TUBB1, TUBB2B, TUBB8, TUBB6, TUBB4A, TUBA3C and TUBA1B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%eribulin mesylate%" OR LOWER(tradeNames_string) LIKE "%eribulin mesylate%" OR LOWER(drugSynonyms_string) LIKE "%eribulin mesylate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3175', 'drugName': 'Eribulin Mesylate', 'tradeNames_string': 'Halaven', 'drugSynonyms_string': 'E-7389, E7389, Eribulin (as mesylate), Eribulin mesilate, Eribulin mesylate, Eribulin monomethanesulfonate, Halaven', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Urothelial Carcinoma (EFO_0008528), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Breast Neoplasm (EFO_0003869), Primary Brain Neoplasm (MONDO_0021632), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Male Breast Carcinoma (EFO_0006861), Urethra Cancer (MONDO_0004192), Triple-Negative Breast Cancer (EFO_0005537), Soft Tissue Sarcoma (EFO_1001968), Salivary Gland Cancer (MONDO_0004669), Cervical Cancer (MONDO_0002974), Head And Neck Malignant Neoplasia (EFO_0006859), Osteosarcoma (EFO_0000637), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060)', 'yearOfFirstApproval': 2010, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'numberLinkedTargets': 15}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.507 | Q17 | What gene does the drug Scopolamine target? | The drug Scopolamine targets the gene CHRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%scopolamine%" OR LOWER(tradeNames_string) LIKE "%scopolamine%" OR LOWER(drugSynonyms_string) LIKE "%scopolamine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2695', 'drugName': 'Methscopolamine Bromide', 'tradeNames_string': 'Methscopolamine bromide, Pamine, Pamine forte', 'drugSynonyms_string': '(-)-Scopolamine Methyl Bromide, Epoxytropine tropate methylbromide, Holopon, Hyoscine methobromide, Methscopolamine bromide, Methylscopolamine bromide, N-methylscopolamine bromide, N-methylscopolamine methylsulfate, NSC-120606, Scopolamine methyl bromide, Scopolamine methylbromide', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1953, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM1 (ENSG00000168539), CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3039', 'drugName': 'Scopolamine', 'tradeNames_string': 'Isoptpo Hyoscine, Scopolamine, Transderm scop', 'drugSynonyms_string': 'Scopolamine', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975), Unipolar Depression (EFO_0003761), Infection (EFO_0000544), Nausea (HP_0002018), Amyotrophic Lateral Sclerosis (MONDO_0004976), Motion Sickness (EFO_0006928), Nausea And Vomiting (HP_0002017), Pain (EFO_0003843), Renal Colic (EFO_1001412), Drooling (HP_0002307), Dementia (HP_0000726), Abdominal Pain (HP_0002027), Post Operative Nausea And Vomiting (EFO_0004888), Major Depressive Disorder (MONDO_0002009), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Social Anxiety Disorder (EFO_1001917)', 'yearOfFirstApproval': 1979, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM1 (ENSG00000168539)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2031', 'drugName': 'Methscopolamine', 'tradeNames_string': '', 'drugSynonyms_string': '(-)-n-methylscopolamine, Methscopolamine cation, Methscopolamine ion, Methylscopolamine, N-methylhyoscine, N-methylscopolamine', 'linkedDiseasesDrug_string': 'Gastrointestinal Disease (EFO_0010282)', 'yearOfFirstApproval': 1953, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM1 (ENSG00000168539), CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2696', 'drugName': 'Methscopolamine Bromide', 'tradeNames_string': 'Methscopolamine bromide, Pamine, Pamine forte', 'drugSynonyms_string': '(-)-Scopolamine Methyl Bromide, Epoxytropine tropate methylbromide, Holopon, Hyoscine methobromide, Methscopolamine bromide, Methylscopolamine bromide, N-methylscopolamine bromide, N-methylscopolamine methylsulfate, NSC-120606, Scopolamine methyl bromide, Scopolamine methylbromide', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1953, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM1 (ENSG00000168539), CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2032', 'drugName': 'Methscopolamine', 'tradeNames_string': '', 'drugSynonyms_string': '(-)-n-methylscopolamine, Methscopolamine cation, Methscopolamine ion, Methylscopolamine, N-methylhyoscine, N-methylscopolamine', 'linkedDiseasesDrug_string': 'Gastrointestinal Disease (EFO_0010282)', 'yearOfFirstApproval': 1953, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM1 (ENSG00000168539), CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.746 | Q17 | What gene does the drug Ethopropazine Hydrochloride target? | The drug Ethopropazine Hydrochloride targets the gene CHRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ethopropazine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%ethopropazine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%ethopropazine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3507', 'drugName': 'Ethopropazine Hydrochloride', 'tradeNames_string': 'Parsidol', 'drugSynonyms_string': 'Ethopropazine hcl, Ethopropazine hydrochloride, NSC-169467, NSC-64074, Profenamine, Profenamine hibenzate, Profenamine hydrochloride, Prophenamine hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM1 (ENSG00000168539)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1851 | Q17 | What gene does the drug Zonisamide target? | The drug Zonisamide targets 10 genes: SCN1A, SCN9A, SCN7A, SCN8A, SCN11A, SCN10A, SCN2A, SCN5A, SCN4A and SCN3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%zonisamide%" OR LOWER(tradeNames_string) LIKE "%zonisamide%" OR LOWER(drugSynonyms_string) LIKE "%zonisamide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_315', 'drugName': 'Zonisamide', 'tradeNames_string': 'Zonegran, Zonisade, Zonisamide', 'drugSynonyms_string': 'AD-810, CI-912, Excegran, N03AX15, PD-110843, Zonisade, Zonisamide', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277), Obesity (EFO_0001073), Focal-Onset Seizure (HP_0007359), Eating Disorder (EFO_0005203), Alcohol Abuse (MONDO_0002046), Nicotine Dependence (EFO_0003768), Schizoaffective Disorder (EFO_0005411), Parkinson Disease (MONDO_0005180), Hearing Loss (EFO_0004238), Cocaine Dependence (EFO_0002610), Epilepsy (EFO_0000474), Seizure (HP_0001250), Complex Partial Epilepsy (EFO_1000877), Alcohol Dependence (MONDO_0007079), Smoking Cessation (EFO_0004319), Essential Tremor (EFO_0003108), Body Weight Gain (EFO_0004566), Noise-Induced Hearing Loss (EFO_1001254), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.875 | Q17 | What gene does the drug Oxcarbazepine target? | The drug Oxcarbazepine targets 10 genes: SCN1A, SCN9A, SCN7A, SCN8A, SCN11A, SCN10A, SCN2A, SCN5A, SCN4A and SCN3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%oxcarbazepine%" OR LOWER(tradeNames_string) LIKE "%oxcarbazepine%" OR LOWER(drugSynonyms_string) LIKE "%oxcarbazepine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1913', 'drugName': 'Oxcarbazepine', 'tradeNames_string': 'Oxcarbazepine, Oxtellar xr, Trileptal', 'drugSynonyms_string': 'GP-47680, KIN-493, NSC-758693, Oxcarbamazepine, Oxcarbazepine, SPN-804', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Aggressive Behavior (EFO_0003015), Multiple Sclerosis (MONDO_0005301), Agitation (HP_0000713), Dementia (HP_0000726), Neuropathic Pain (EFO_0005762), Anxiety (EFO_0005230), Partial Epilepsy (EFO_0004263), Epilepsy (EFO_0000474), Depressive Disorder (MONDO_0002050), Seizure (HP_0001250), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.738 | Q17 | What gene does the drug Aprotinin target? | The drug Aprotinin targets 2 genes: PLG and KLKB1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%aprotinin%" OR LOWER(tradeNames_string) LIKE "%aprotinin%" OR LOWER(drugSynonyms_string) LIKE "%aprotinin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4053', 'drugName': 'Aprotinin', 'tradeNames_string': 'Trasylol', 'drugSynonyms_string': 'Aprotinin, Aprotinin (bovine), Aprotinin (synthetic), Aprotinin biosynthetic, Aprotinin bovine, Aprotinin concentrated solution, BAYER A 128, BAYER-A-128, BAYERA-128, Bovine aprotinin, Fibrinolysis inhibitor, RIKER 52G, RIKER-52G, RP 9921, RP-9921', 'linkedDiseasesDrug_string': 'Hemorrhage (MP_0001914), Pancreatitis (EFO_0000278), Breast Cancer (MONDO_0007254)', 'yearOfFirstApproval': 1993, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PLG (ENSG00000122194), KLKB1 (ENSG00000164344)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4054', 'drugName': 'Aprotinin', 'tradeNames_string': 'Trasylol', 'drugSynonyms_string': 'Aprotinin, Aprotinin (bovine), Aprotinin (synthetic), Aprotinin biosynthetic, Aprotinin bovine, Aprotinin concentrated solution, BAYER A 128, BAYER-A-128, BAYERA-128, Bovine aprotinin, Fibrinolysis inhibitor, RIKER 52G, RIKER-52G, RP 9921, RP-9921', 'linkedDiseasesDrug_string': 'Hemorrhage (MP_0001914), Pancreatitis (EFO_0000278), Breast Cancer (MONDO_0007254)', 'yearOfFirstApproval': 1993, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PLG (ENSG00000122194), KLKB1 (ENSG00000164344)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.545 | Q17 | What gene does the drug Pertuzumab target? | The drug Pertuzumab targets the gene ERBB2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pertuzumab%" OR LOWER(tradeNames_string) LIKE "%pertuzumab%" OR LOWER(drugSynonyms_string) LIKE "%pertuzumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1613', 'drugName': 'Pertuzumab', 'tradeNames_string': 'Omnitarg, Omnitarg Perjeta, Perjeta', 'drugSynonyms_string': 'Pertuzumab, Pertuzumab-zzxf, RG-1273, RHUMAB 2C4, RHUMAB-2C4', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Colorectal Carcinoma (EFO_1001951), Esophageal Carcinoma (EFO_0002916), Gastric Cancer (MONDO_0001056), Angiosarcoma (EFO_0003968), Malignant Colon Neoplasm (MONDO_0021063), Ovarian Cancer (MONDO_0008170), Breast Neoplasm (EFO_0003869), Neuroendocrine Carcinoma (MONDO_0002120), Breast Carcinoma (EFO_0000305), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Male Breast Carcinoma (EFO_0006861), Metastasis (EFO_0009708), Inflammatory Breast Carcinoma (EFO_1000984), Pancreatic Carcinoma (EFO_0002618), Triple-Negative Breast Cancer (EFO_0005537), Peritoneum Cancer (MONDO_0002087), Rectum Cancer (EFO_1000657), Fallopian Tube Cancer (MONDO_0002158), Neoplasm (EFO_0000616), Colorectal Adenocarcinoma (EFO_0000365), Non-Small Cell Lung Carcinoma (EFO_0003060)', 'yearOfFirstApproval': 2012, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ERBB2 (ENSG00000141736)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1211 | Q17 | What gene does the drug Imipramine Pamoate target? | The drug Imipramine Pamoate targets 2 genes: SLC6A4 and SLC6A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%imipramine pamoate%" OR LOWER(tradeNames_string) LIKE "%imipramine pamoate%" OR LOWER(drugSynonyms_string) LIKE "%imipramine pamoate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_654', 'drugName': 'Imipramine Pamoate', 'tradeNames_string': 'Imipramine pamoate, Tofranil-pm', 'drugSynonyms_string': 'Imipramine embonate, Imipramine pamoate', 'linkedDiseasesDrug_string': 'Enuresis (MONDO_0024290)', 'yearOfFirstApproval': 1973, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_655', 'drugName': 'Imipramine Pamoate', 'tradeNames_string': 'Imipramine pamoate, Tofranil-pm', 'drugSynonyms_string': 'Imipramine embonate, Imipramine pamoate', 'linkedDiseasesDrug_string': 'Enuresis (MONDO_0024290)', 'yearOfFirstApproval': 1973, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.704 | Q17 | What gene does the drug Danicamtiv target? | The drug Danicamtiv is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 7 genes: MYL7, MYH6, MYL3, MYL4, MYL2, MYH7B and MYH7 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%danicamtiv%" OR LOWER(tradeNames_string) LIKE "%danicamtiv%" OR LOWER(drugSynonyms_string) LIKE "%danicamtiv%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2405', 'drugName': 'Danicamtiv', 'tradeNames_string': '', 'drugSynonyms_string': 'Danicamtiv, MYK-491, MYK491, Myk-491, SAR-440181, SAR440181', 'linkedDiseasesDrug_string': 'Dilated Cardiomyopathy (EFO_0000407)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'MYH7 (ENSG00000092054), MYH6 (ENSG00000197616), MYH7B (ENSG00000078814), MYL3 (ENSG00000160808), MYL2 (ENSG00000111245), MYL7 (ENSG00000106631), MYL4 (ENSG00000198336)', 'numberLinkedTargets': 7}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1394 | Q17 | What gene does the drug Galantamine Hydrobromide target? | The drug Galantamine Hydrobromide targets the gene ACHE. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%galantamine hydrobromide%" OR LOWER(tradeNames_string) LIKE "%galantamine hydrobromide%" OR LOWER(drugSynonyms_string) LIKE "%galantamine hydrobromide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1632', 'drugName': 'Galantamine Hydrobromide', 'tradeNames_string': 'Galantamine hydrobromide, Razadyne, Razadyne er', 'drugSynonyms_string': '(-)-galantamine hydrobromide, Galantamine hydrobromide, Galanthamine hydrobromide, Jilkon hydrobromide, Lycoremine hydrobromide, Nivalin, Nivaline, Tamilin', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975), Frontotemporal Dementia (MONDO_0017276), Cognitive Impairment (HP_0100543), Mental Or Behavioural Disorder (EFO_0000677), Dementia (HP_0000726), Schizophrenia (MONDO_0005090), Vascular Dementia (EFO_0004718)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACHE (ENSG00000087085)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1783 | Q17 | What gene does the drug Efatutazone target? | The drug Efatutazone is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene PPARG. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%efatutazone%" OR LOWER(tradeNames_string) LIKE "%efatutazone%" OR LOWER(drugSynonyms_string) LIKE "%efatutazone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4028', 'drugName': 'Efatutazone', 'tradeNames_string': '', 'drugSynonyms_string': 'Efatutazone, Inolitazone', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Colorectal Adenocarcinoma (EFO_0000365), Thyroid Cancer (MONDO_0002108), Liposarcoma (EFO_0000569), Colorectal Carcinoma (EFO_1001951)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'PPARG (ENSG00000132170)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3103', 'drugName': 'Efatutazone Hydrochloride', 'tradeNames_string': '', 'drugSynonyms_string': 'CS-7017, Efatutazone dihydrochloride, Efatutazone hydrochloride, Inolitazone dihydrochloride, RS5444', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'PPARG (ENSG00000132170)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1155 | Q17 | What gene does the drug Capromorelin target? | The drug Capromorelin is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene GHSR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%capromorelin%" OR LOWER(tradeNames_string) LIKE "%capromorelin%" OR LOWER(drugSynonyms_string) LIKE "%capromorelin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1109', 'drugName': 'Capromorelin', 'tradeNames_string': '', 'drugSynonyms_string': 'CP-424,391, CP-424391-18, Capimorelin, Capromorelin, Cp-424,391, Cp-424391', 'linkedDiseasesDrug_string': 'Aging (GO_0007568)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'GHSR (ENSG00000121853)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1040 | Q17 | What gene does the drug Brigatinib target? | The drug Brigatinib targets 2 genes: ALK and EGFR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%brigatinib%" OR LOWER(tradeNames_string) LIKE "%brigatinib%" OR LOWER(drugSynonyms_string) LIKE "%brigatinib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1566', 'drugName': 'Brigatinib', 'tradeNames_string': 'Alunbrig', 'drugSynonyms_string': 'AP-26113, AP26113, Ap-26113, Brigatinib', 'linkedDiseasesDrug_string': 'Anaplastic Large Cell Lymphoma (EFO_0003032), Non-Small Cell Lung Carcinoma (EFO_0003060), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 2017, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EGFR (ENSG00000146648), ALK (ENSG00000171094)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1567', 'drugName': 'Brigatinib', 'tradeNames_string': 'Alunbrig', 'drugSynonyms_string': 'AP-26113, AP26113, Ap-26113, Brigatinib', 'linkedDiseasesDrug_string': 'Anaplastic Large Cell Lymphoma (EFO_0003032), Non-Small Cell Lung Carcinoma (EFO_0003060), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 2017, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EGFR (ENSG00000146648), ALK (ENSG00000171094)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.378 | Q17 | What gene does the drug Ag-24322 target? | The drug Ag-24322 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 3 genes: CDK4, CDK2 and CDK1 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ag-24322%" OR LOWER(tradeNames_string) LIKE "%ag-24322%" OR LOWER(drugSynonyms_string) LIKE "%ag-24322%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1526', 'drugName': 'Ag-24322', 'tradeNames_string': '', 'drugSynonyms_string': 'AG-024322, Ag 024322, Ag-24322', 'linkedDiseasesDrug_string': 'Non-Hodgkins Lymphoma (EFO_0005952)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'CDK4 (ENSG00000135446), CDK2 (ENSG00000123374), CDK1 (ENSG00000170312)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_1527', 'drugName': 'Ag-24322', 'tradeNames_string': '', 'drugSynonyms_string': 'AG-024322, Ag 024322, Ag-24322', 'linkedDiseasesDrug_string': 'Non-Hodgkins Lymphoma (EFO_0005952)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'CDK4 (ENSG00000135446), CDK2 (ENSG00000123374), CDK1 (ENSG00000170312)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_1528', 'drugName': 'Ag-24322', 'tradeNames_string': '', 'drugSynonyms_string': 'AG-024322, Ag 024322, Ag-24322', 'linkedDiseasesDrug_string': 'Non-Hodgkins Lymphoma (EFO_0005952)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'CDK4 (ENSG00000135446), CDK2 (ENSG00000123374), CDK1 (ENSG00000170312)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.674 | Q17 | What gene does the drug Benziodarone target? | The drug Benziodarone targets the gene CALM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%benziodarone%" OR LOWER(tradeNames_string) LIKE "%benziodarone%" OR LOWER(drugSynonyms_string) LIKE "%benziodarone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1971', 'drugName': 'Benziodarone', 'tradeNames_string': '', 'drugSynonyms_string': 'Amplivix, Benziodarone, L 2329, L-2329, NSC-82133', 'linkedDiseasesDrug_string': 'Cardiovascular Disease (EFO_0000319)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CALM1 (ENSG00000198668)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1527 | Q17 | What gene does the drug Antipyrine target? | The drug Antipyrine targets the gene PTGS1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%antipyrine%" OR LOWER(tradeNames_string) LIKE "%antipyrine%" OR LOWER(drugSynonyms_string) LIKE "%antipyrine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3434', 'drugName': 'Antipyrine', 'tradeNames_string': '', 'drugSynonyms_string': 'Antipyrin, Antipyrine, Antipyrinum, NSC-7945, Phenazon, Phenazone', 'linkedDiseasesDrug_string': 'Asthma (MONDO_0004979), Pain (EFO_0003843), Fever (HP_0001945), Dysmenorrhea (HP_0100607), Otitis Media (EFO_0004992)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.362 | Q17 | What gene does the drug Ketorolac target? | The drug Ketorolac targets 2 genes: PTGS2 and PTGS1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ketorolac%" OR LOWER(tradeNames_string) LIKE "%ketorolac%" OR LOWER(drugSynonyms_string) LIKE "%ketorolac%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2258', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_string': 'Acular, Acular ls, Acular preservative free, Acuvail, Ketorolac tromethamine, Sprix, Toradol', 'drugSynonyms_string': 'Dolac, Ketorolac trometamol, Ketorolac tromethamine, Lixidol, NSC-758637, Tarasyn', 'linkedDiseasesDrug_string': 'Heart Disease (EFO_0003777), Cerebral Arterial Disease (EFO_1000859), Pulpitis (EFO_1001139), Cataract (MONDO_0005129), Migraine Disorder (MONDO_0005277), Renal Colic (EFO_1001412), Pain (EFO_0003843), Ocular Pain (HP_0200026), Back Pain (HP_0003418), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Inflammation (MP_0001845), Allergic Rhinitis (EFO_0005854), Shoulder Impingement Syndrome (EFO_1001178), Nephrolithiasis (EFO_0004253), Macular Retinal Edema (MONDO_0003005)', 'yearOfFirstApproval': 1989, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4826', 'drugName': 'Ketorolac', 'tradeNames_string': '', 'drugSynonyms_string': 'Ketorolac', 'linkedDiseasesDrug_string': 'Rheumatic Disease (EFO_0005755), Pain (EFO_0003843), Ocular Pain (HP_0200026), Migraine Disorder (MONDO_0005277), Abdominal Pain (HP_0002027), Allergic Rhinitis (EFO_0005854), Injury (EFO_0000546), Musculoskeletal System Disease (EFO_0009676), Nephrolithiasis (EFO_0004253), Ovarian Cancer (MONDO_0008170), Breast Neoplasm (EFO_0003869), Headache (HP_0002315), Preeclampsia (EFO_0000668), Cerebral Arterial Disease (EFO_1000859), Rotator Cuff Tear (EFO_1001250), Cataract (MONDO_0005129), Diabetic Retinopathy (EFO_0003770), Eye Inflammation (EFO_0005752), Miosis (HP_0000616), Osteoarthritis, Knee (EFO_0004616), Viral Conjunctivitis (EFO_0008571), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Scoliosis (EFO_0004273), Periodontitis (EFO_0000649), Acute Pancreatitis (EFO_1000652), Retinopathy Of Prematurity (EFO_1001158), Renal Colic (EFO_1001412), Back Pain (HP_0003418), Peritoneum Cancer (MONDO_0002087), Inflammation (MP_0001845), Recurrent Tonsillitis (HP_0011110), Macular Retinal Edema (MONDO_0003005), Heart Disease (EFO_0003777), Fallopian Tube Cancer (MONDO_0002158), Pulpitis (EFO_1001139), Chronic Pain (HP_0012532), Dysphagia (HP_0002015), Shoulder Impingement Syndrome (EFO_1001178), Hypoxia (EFO_0009444)', 'yearOfFirstApproval': 1989, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.976 | Q17 | What gene does the drug Dinoprost target? | The drug Dinoprost targets the gene PTGFR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dinoprost%" OR LOWER(tradeNames_string) LIKE "%dinoprost%" OR LOWER(drugSynonyms_string) LIKE "%dinoprost%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1161', 'drugName': 'Dinoprost', 'tradeNames_string': '', 'drugSynonyms_string': 'Dinoprost, Pgf2a, Pgf2alpha, Prosmon, Prostaglandin f2-alpha, Prostaglandin f2.alpha., Prostaglandin f2alpha, U-14,583, U-14583', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGFR (ENSG00000122420)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3570', 'drugName': 'Dinoprost Tromethamine', 'tradeNames_string': 'Dinoprost Trometamol, Lutalyse, PGF2A, Prostaglandin F 2 Alpha, Prostin f2 alpha', 'drugSynonyms_string': 'Dinoprost trometamol, Dinoprost tromethamine, NSC-196515, PGF2A THAM, PGF2ALPHA THAM, U-14,583E, U-14-583E, U-14583E', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGFR (ENSG00000122420)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4965', 'drugName': 'Dinoprostone', 'tradeNames_string': 'Cervidil, Prepidil, Propess, Prostin e2', 'drugSynonyms_string': 'Dinoprostone, Dinoprostone beta-cyclodextrin clathrate, Enzaprost e, Minprostin e2, NSC-165560, NSC-196514, Prostaglandin e2, U-12,062, U-12062', 'linkedDiseasesDrug_string': 'Pregnancy (EFO_0002950), Pain (EFO_0003843), Incomplete Abortion (EFO_1001799)', 'yearOfFirstApproval': 1977, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGER1 (ENSG00000160951), PTGER4 (ENSG00000171522), PTGER2 (ENSG00000125384), PTGER3 (ENSG00000050628)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.790 | Q17 | What gene does the drug Insulin Aspart Protamine Recombinant target? | The drug Insulin Aspart Protamine Recombinant targets the gene INSR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%insulin aspart protamine recombinant%" OR LOWER(tradeNames_string) LIKE "%insulin aspart protamine recombinant%" OR LOWER(drugSynonyms_string) LIKE "%insulin aspart protamine recombinant%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1048', 'drugName': 'Insulin Aspart Protamine Recombinant', 'tradeNames_string': '', 'drugSynonyms_string': 'Insulin aspart protamine recombinant', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.742 | Q17 | What gene does the drug Tramadol target? | The drug Tramadol targets the gene OPRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tramadol%" OR LOWER(tradeNames_string) LIKE "%tramadol%" OR LOWER(drugSynonyms_string) LIKE "%tramadol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5530', 'drugName': 'Tramadol', 'tradeNames_string': '', 'drugSynonyms_string': 'Amanda, CG-315E, E-265, ETS-6103, ETS6103, Tramadol, U-26255A, Ultracet, Ultram', 'linkedDiseasesDrug_string': 'Toothache (EFO_0010072), Cancer (MONDO_0004992), Hip Fracture (EFO_0003964), Pain (EFO_0003843), Abdominal Pain (HP_0002027), Injury (EFO_0000546), Substance Withdrawal Syndrome (EFO_0005800), Breast Cancer (MONDO_0007254), Rotator Cuff Tear (EFO_1001250), Osteoarthritis, Knee (EFO_0004616), Neuropathic Pain (EFO_0005762), Fibromyalgia (EFO_0005687), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Drug Dependence (EFO_0003890), Opioid Dependence (EFO_0005611), Head And Neck Malignant Neoplasia (EFO_0006859), Osteoarthritis (MONDO_0005178), Diabetic Neuropathy (EFO_1000783), Chronic Pain (HP_0012532), Major Depressive Disorder (MONDO_0002009), Low Back Pain (HP_0003419)', 'yearOfFirstApproval': 1995, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3268', 'drugName': 'Tramadol Hydrochloride', 'tradeNames_string': 'Aceon, Conzip, Dromadol sr, Dromadol xl, Invodol sr, Larapam sr, Mabron, Maneo, Marol, Maxitram sr, Nobligan ret, Oldaram, Qdolo, Rybix odt, Ryzolt, Tilodol sr, Tradorec xl, Tramacet, Tramadol hydrochloride, Tramake, Tramake insts, Tramquel sr, Tramulief sr, Ultram, Ultram er, Zamadol, Zamadol 24hr, Zamadol melt, Zamadol sr, Zeridame sr, Zydol, Zydol sr, Zydol xl', 'drugSynonyms_string': 'Amadol, CG-315, CG-315E, Contramal, NIH-10969, NSC-759105, Tradonal, Tramadol hcl, Tramadol hydrochloride, Tramadol hydrochloride civ, Tramal, U-26,225A, U-26225A, Zamudol, Zertane', 'linkedDiseasesDrug_string': 'Toothache (EFO_0010072), Cancer (MONDO_0004992), Drug Dependence (EFO_0003890), Pain (EFO_0003843), Chronic Pain (HP_0012532), Low Back Pain (HP_0003419)', 'yearOfFirstApproval': 1995, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1044 | Q17 | What gene does the drug Zolpidem Tartrate target? | The drug Zolpidem Tartrate targets 3 genes: GABRG2, GABRA1 and GABRB1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%zolpidem tartrate%" OR LOWER(tradeNames_string) LIKE "%zolpidem tartrate%" OR LOWER(drugSynonyms_string) LIKE "%zolpidem tartrate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5904', 'drugName': 'Zolpidem Tartrate', 'tradeNames_string': 'Ambien, Ambien cr, Edluar, Intermezzo, Stilnoct, Tovalt odt, Zolpidem tartrate, Zolpimist', 'drugSynonyms_string': 'Ivadal, Myslee, Niotal, SL 80.0750-23N, SL-80.0750, SL-80.0750-23N, Stilnox, Tovalt, Zolpidem hemitartrate, Zolpidem tartrate, Zolpidem tartrate civ', 'linkedDiseasesDrug_string': 'Sleep Disorder (EFO_0008568), Obesity (EFO_0001073), Insomnia (EFO_0004698)', 'yearOfFirstApproval': 1992, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRG2 (ENSG00000113327), GABRB1 (ENSG00000163288)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.979 | Q17 | What gene does the drug Canertinib target? | The drug Canertinib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 3 genes: ERBB2, ERBB4 and EGFR | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%canertinib%" OR LOWER(tradeNames_string) LIKE "%canertinib%" OR LOWER(drugSynonyms_string) LIKE "%canertinib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5062', 'drugName': 'Canertinib', 'tradeNames_string': '', 'drugSynonyms_string': 'CI-1033, Canertinib', 'linkedDiseasesDrug_string': 'Breast Neoplasm (EFO_0003869), Lung Neoplasm (MONDO_0021117), Non-Small Cell Lung Carcinoma (EFO_0003060)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'ERBB2 (ENSG00000141736), ERBB4 (ENSG00000178568), EGFR (ENSG00000146648)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_4701', 'drugName': 'Canertinib Dihydrochloride', 'tradeNames_string': '', 'drugSynonyms_string': 'CI-1033, Canertinib dihydrochloride, Canertinib hydrochloride, PD-0183805, PD-0183805-002B, PD-183805, SN-26606', 'linkedDiseasesDrug_string': 'Breast Neoplasm (EFO_0003869), Lung Neoplasm (MONDO_0021117), Non-Small Cell Lung Carcinoma (EFO_0003060)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'EGFR (ENSG00000146648), ERBB2 (ENSG00000141736), ERBB4 (ENSG00000178568)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_4700', 'drugName': 'Canertinib Dihydrochloride', 'tradeNames_string': '', 'drugSynonyms_string': 'CI-1033, Canertinib dihydrochloride, Canertinib hydrochloride, PD-0183805, PD-0183805-002B, PD-183805, SN-26606', 'linkedDiseasesDrug_string': 'Breast Neoplasm (EFO_0003869), Lung Neoplasm (MONDO_0021117), Non-Small Cell Lung Carcinoma (EFO_0003060)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'EGFR (ENSG00000146648), ERBB2 (ENSG00000141736), ERBB4 (ENSG00000178568)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_5060', 'drugName': 'Canertinib', 'tradeNames_string': '', 'drugSynonyms_string': 'CI-1033, Canertinib', 'linkedDiseasesDrug_string': 'Breast Neoplasm (EFO_0003869), Lung Neoplasm (MONDO_0021117), Non-Small Cell Lung Carcinoma (EFO_0003060)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'ERBB2 (ENSG00000141736), ERBB4 (ENSG00000178568), EGFR (ENSG00000146648)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_5061', 'drugName': 'Canertinib', 'tradeNames_string': '', 'drugSynonyms_string': 'CI-1033, Canertinib', 'linkedDiseasesDrug_string': 'Breast Neoplasm (EFO_0003869), Lung Neoplasm (MONDO_0021117), Non-Small Cell Lung Carcinoma (EFO_0003060)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'ERBB2 (ENSG00000141736), ERBB4 (ENSG00000178568), EGFR (ENSG00000146648)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_4702', 'drugName': 'Canertinib Dihydrochloride', 'tradeNames_string': '', 'drugSynonyms_string': 'CI-1033, Canertinib dihydrochloride, Canertinib hydrochloride, PD-0183805, PD-0183805-002B, PD-183805, SN-26606', 'linkedDiseasesDrug_string': 'Breast Neoplasm (EFO_0003869), Lung Neoplasm (MONDO_0021117), Non-Small Cell Lung Carcinoma (EFO_0003060)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'EGFR (ENSG00000146648), ERBB2 (ENSG00000141736), ERBB4 (ENSG00000178568)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1526 | Q17 | What gene does the drug Ethopropazine target? | The drug Ethopropazine targets the gene CHRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ethopropazine%" OR LOWER(tradeNames_string) LIKE "%ethopropazine%" OR LOWER(drugSynonyms_string) LIKE "%ethopropazine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5173', 'drugName': 'Ethopropazine', 'tradeNames_string': '', 'drugSynonyms_string': 'Ethopropazine, Parsidol, Profenamine', 'linkedDiseasesDrug_string': 'Parkinson Disease (MONDO_0005180)', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM1 (ENSG00000168539)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3507', 'drugName': 'Ethopropazine Hydrochloride', 'tradeNames_string': 'Parsidol', 'drugSynonyms_string': 'Ethopropazine hcl, Ethopropazine hydrochloride, NSC-169467, NSC-64074, Profenamine, Profenamine hibenzate, Profenamine hydrochloride, Prophenamine hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM1 (ENSG00000168539)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1488 | Q17 | What gene does the drug Darolutamide target? | The drug Darolutamide targets the gene AR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%darolutamide%" OR LOWER(tradeNames_string) LIKE "%darolutamide%" OR LOWER(drugSynonyms_string) LIKE "%darolutamide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5106', 'drugName': 'Darolutamide', 'tradeNames_string': 'Nubeqa', 'drugSynonyms_string': 'BAY 1841788, BAY-1841788, BAY1841788, Darolutamide, ODM-201, Odm-201', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Metastatic Prostate Cancer (EFO_0000196), Prostate Carcinoma (EFO_0001663), Prostate Adenocarcinoma (EFO_0000673)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1525 | Q17 | What gene does the drug Chlorphentermine target? | The drug Chlorphentermine targets the gene SLC6A4. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%chlorphentermine%" OR LOWER(tradeNames_string) LIKE "%chlorphentermine%" OR LOWER(drugSynonyms_string) LIKE "%chlorphentermine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6215', 'drugName': 'Chlorphentermine', 'tradeNames_string': '', 'drugSynonyms_string': 'Chlorphentermine', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4353', 'drugName': 'Chlorphentermine Hydrochloride', 'tradeNames_string': 'Pre-sate', 'drugSynonyms_string': 'Chlorphentermine hcl, Chlorphentermine hydrochloride, NSC-76098, S-62, W 2426, W-2426', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1492 | Q17 | What gene does the drug Monobenzone target? | The drug Monobenzone targets the gene TYR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%monobenzone%" OR LOWER(tradeNames_string) LIKE "%monobenzone%" OR LOWER(drugSynonyms_string) LIKE "%monobenzone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3683', 'drugName': 'Monobenzone', 'tradeNames_string': 'Benoquin', 'drugSynonyms_string': 'Monobenzone, Monobenzyl ether of hydroquinone, NSC-2132, P-(benzyloxy)phenol, P-benzyloxyphenol', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1952, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TYR (ENSG00000077498)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1694 | Q17 | What gene does the drug Vandortuzumab Vedotin target? | The drug Vandortuzumab Vedotin is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 16 genes: TUBB, TUBA4A, TUBA3E, TUBB3, TUBB4B, TUBB2A, STEAP1, TUBA1A, TUBA1C, TUBB1, TUBB2B, TUBB8, TUBB6, TUBB4A, TUBA3C and TUBA1B | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vandortuzumab vedotin%" OR LOWER(tradeNames_string) LIKE "%vandortuzumab vedotin%" OR LOWER(drugSynonyms_string) LIKE "%vandortuzumab vedotin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_752', 'drugName': 'Vandortuzumab Vedotin', 'tradeNames_string': '', 'drugSynonyms_string': 'DSTP3086S, MSTP2109A, RG-7450, RG7450, Vandortuzumab vedotin', 'linkedDiseasesDrug_string': 'Prostate Cancer (MONDO_0008315)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'STEAP1 (ENSG00000164647), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'numberLinkedTargets': 16}, {'UUID': 'DrugGeneTargets_v2_753', 'drugName': 'Vandortuzumab Vedotin', 'tradeNames_string': '', 'drugSynonyms_string': 'DSTP3086S, MSTP2109A, RG-7450, RG7450, Vandortuzumab vedotin', 'linkedDiseasesDrug_string': 'Prostate Cancer (MONDO_0008315)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'STEAP1 (ENSG00000164647), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'numberLinkedTargets': 16}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1716 | Q17 | What gene does the drug Tralokinumab target? | The drug Tralokinumab targets the gene IL13. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tralokinumab%" OR LOWER(tradeNames_string) LIKE "%tralokinumab%" OR LOWER(drugSynonyms_string) LIKE "%tralokinumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6079', 'drugName': 'Tralokinumab', 'tradeNames_string': 'Adbry', 'drugSynonyms_string': 'CAT-354, Tralokinumab', 'linkedDiseasesDrug_string': 'Eczema (HP_0000964), Pancreatic Carcinoma (EFO_0002618), Asthma (MONDO_0004979), Alopecia Areata (EFO_0004192), Atopic Eczema (EFO_0000274), Idiopathic Pulmonary Fibrosis (EFO_0000768), Ulcerative Colitis (EFO_0000729)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IL13 (ENSG00000169194)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1246 | Q17 | What gene does the drug Hydrochlorothiazide target? | The drug Hydrochlorothiazide targets the gene SLC12A3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%hydrochlorothiazide%" OR LOWER(tradeNames_string) LIKE "%hydrochlorothiazide%" OR LOWER(drugSynonyms_string) LIKE "%hydrochlorothiazide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4705', 'drugName': 'Chlorothiazide', 'tradeNames_string': 'Chlorothiazide, Diuril, Saluric', 'drugSynonyms_string': 'Chlorothiazide, Chlorthiazide, Hydrochlorothiazide impurity, chlorothiazide-, NSC-25693', 'linkedDiseasesDrug_string': 'Nephrotic Syndrome (EFO_0004255), Edema (EFO_0009373), Heart Disease (EFO_0003777), Chronic Kidney Disease (EFO_0003884), Congestive Heart Failure (EFO_0000373), Coronary Artery Disease (EFO_0001645), Preeclampsia (EFO_0000668), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Hypercholesterolemia (HP_0003124), Glomerulonephritis (MONDO_0002462), Type 2 Diabetes Mellitus (MONDO_0005148), Atherosclerosis (EFO_0003914)', 'yearOfFirstApproval': 1958, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC12A3 (ENSG00000070915)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1678', 'drugName': 'Hydrochlorothiazide', 'tradeNames_string': 'Apo-hydro, Esidrex, Esidrix, Hydro-d, Hydrochlorothiazide, Hydrochlorothiazide intensol, Hydrodiuril, Hydrosaluric, Microzide, Oretic, Zide', 'drugSynonyms_string': 'Apresazide, Carozide, Chlorosulthiadil, Copalia-hct, Dafiro-hct, Dihydrochlorurite, Exforge-hct, Hctz, Hidrotiazida, Hydrochlorothiaizide, Hydrochlorothiazide, Hydrochlorothiazidum, Idrotiazide, Imprida-hct, Lotensin hct, Megadiuril, NSC-53477, Newtolide, Pantemon, Rasilez-hct, SU-5879, Servithiazid, Unipres, Vetidrex', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Coronary Artery Disease (EFO_0001645), Essential Hypertension (MONDO_0001134), Glomerulonephritis (MONDO_0002462), Nephrolithiasis (EFO_0004253), Edema (EFO_0009373), Nephrotic Syndrome (EFO_0004255), Congestive Heart Failure (EFO_0000373), Preeclampsia (EFO_0000668), Angina Pectoris (EFO_0003913), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Autosomal Dominant Polycystic Kidney Disease (EFO_1001496), Fish-Eye Disease (Orphanet_79292), Sudden Cardiac Arrest (EFO_0004278), Myocardial Infarction (EFO_0000612), Hypercholesterolemia (HP_0003124), Chronic Kidney Disease (EFO_0003884), Metabolic Syndrome (EFO_0000195), Kidney Disease (EFO_0003086), Type 2 Diabetes Mellitus (MONDO_0005148), Atherosclerosis (EFO_0003914), Cirrhosis Of Liver (EFO_0001422)', 'yearOfFirstApproval': 1959, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC12A3 (ENSG00000070915)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.